



Published in final edited form as:

Connect Tissue Res. 2017 January ; 58(1): 116–141. doi:10.1080/03008207.2016.1194406.

Emerging roles for long noncoding RNAs in skeletal biology and disease

Nguyen P. T. Huynh^{a,b,c,*}, Britta A. Anderson^{a,*}, Farshid Guilak^{a,b,c,e,f}, and Audrey McAlinden^{a,d,e}

^aDepartment of Orthopaedic Surgery, Washington University School of Medicine, St Louis, MO, USA

^bShriners Hospitals for Children – St. Louis, St. Louis, MO, USA

^cDepartment of Cell Biology, Duke University Medical Center, Durham, NC, USA

^dDepartment of Cell Biology & Physiology, Washington University School of Medicine, St. Louis, MO, USA

^eDepartment of Biomedical Engineering, Washington University School of Medicine, St. Louis, MO, USA

^fDepartment of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA

Abstract

Normal skeletal development requires tight coordination of transcriptional networks, signaling pathways, and biomechanical cues, and many of these pathways are dysregulated in pathological conditions affecting cartilage and bone. Recently, a significant role has been identified for long noncoding RNAs (lncRNAs) in developing and maintaining cellular phenotypes, and improvements in sequencing technologies have led to the identification of thousands of lncRNAs across diverse cell types, including the cells within cartilage and bone. It is clear that lncRNAs play critical roles in regulating gene expression. For example, they can function as epigenetic regulators in the nucleus via chromatin modulation to control gene transcription, or in the cytoplasm, where they can function as scaffolds for protein-binding partners or modulate the activity of other coding and noncoding RNAs. In this review, we discuss the growing list of lncRNAs involved in normal development and/or homeostasis of the skeletal system, the potential mechanisms by which these lncRNAs might function, and recent improvements in the methodologies available to study lncRNA functions *in vitro* and *in vivo*. Finally, we address the likely utility of lncRNAs as biomarkers and therapeutic targets for diseases of the skeletal system, including osteoarthritis, osteoporosis, and in cancers of the skeletal system.

CONTACT Dr. Audrey McAlinden mcalindena@wudosis.wustl.edu Department of Orthopaedic Surgery, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA.

*These authors contributed equally to this work.

Keywords

Bone; cartilage; chondrocyte; long noncoding (lnc) RNAs; osteoarthritis; osteoblast; osteosarcoma

Introduction

The human genome project commenced in 1990, and its first complete assembly was announced in 2003. From this endeavor, it was found that while 70–90% of the human genome is actively transcribed, there is only 1–2% of the genome that contains protein-coding information (1,2). The remaining noncoding RNA (ncRNA) transcripts were found to lack conserved open reading frames (ORFs) and were predicted to have no biological functions in the cell. As such, these ncRNAs were usually initially referred to as “junk RNA.”

However, the past two decades of research on ncRNAs has overwhelmingly shown that these ncRNAs are in fact not “junk,” but rather play crucial and multifunctional roles in the regulation of cell phenotype. For example, classes of short ncRNAs [e.g., microRNAs (miRNAs) and Piwi-interacting RNAs (piRNAs)] have been shown to function as gene silencing agents (3–13). More recently, much interest has focused on another class of ncRNAs, known as long noncoding RNAs (lncRNAs). lncRNAs are defined as any ncRNA containing 200 or more nucleotides. The majority of lncRNAs are transcribed by RNA polymerase II (RNA Pol II), and they are often spliced (and even alternatively spliced) during RNA processing. From the most recent release of GENCODE, it is predicted that there are currently 15,941 human lncRNAs and 8793 mouse lncRNAs (14). In this article, we review the current literature on lncRNAs and their role in skeletal development and maintenance. A summary of the lncRNAs discussed here can be found in Table 1.

lncRNAs: nomenclature and categorization

It is encouraged that lncRNAs should be named based on their functions (15), although at this point, many of their specific functions remain to be determined. For example, *XIST* is named for “X (Inactive)-Specific Transcript” (16,17), while *DANCR* stands for “Differentiation Antagonizing Non-Protein Coding RNA” (18–20). However, when lncRNAs are initially identified without a known function, they are named based on the associated genomic context or assigned an arbitrary name based on the GENCODE categorization, which divides lncRNAs into the following sub-categories (21,22):

1. Antisense: lncRNA whose sequence overlaps the exonic sequence of a protein-coding gene on the opposite strand (e.g., *HIF1a-AS1*)
2. lincRNA: lncRNA located within the intergenic regions of protein-coding genes (e.g., *LINC00152*)
3. Sense-overlapping: lncRNA whose intronic sequences encode a protein-coding or noncoding gene without overlap of exonic sequences (e.g., *SOX2-OT*)
4. Sense intronic: lncRNA residing within introns of a coding gene (e.g., *SPRY-IT1*)

5. Processed transcript: lncRNA that does not contain an ORF and does not fit in any of the above categories

lncRNAs: mechanisms of action

lncRNAs function in diverse ways by virtue of their primary sequence as well as their secondary and tertiary structures. In addition to interacting via base pair complementarity with DNA and RNA partners, they also fold into unique conformations that allow them to interact with DNA, RNA, and proteins. Importantly, these functions are not mutually exclusive, and the unique ability of lncRNAs to utilize these features simultaneously allows them to have far-reaching effects on cellular processes. While a more extensive discussion of the molecular mechanisms of lncRNAs can be found elsewhere (23), in this review we aim to highlight the general mechanisms by which lncRNAs execute their functions and to discuss the growing list of lncRNAs known to be involved in skeletal biology.

lncRNAs in the nucleus

lncRNAs appear to play a number of roles within the nucleus. For example, immunoprecipitation of various chromatin-modifying complexes reveals interactions with many nuclear lncRNAs, indicating a likely function for lncRNAs in epigenetic regulation (24,25). In a variety of vertebrate and invertebrate systems, lncRNAs have been identified that function as scaffolds for repressive chromatin modifiers such as: (i) the Polycomb repressive complexes 1 and 2 (PRC1, PRC2), which methylate histone 3 at lysine 27 (26), (ii) the repressive histone demethylase complex LSD1 (27), which demethylates histone 3 at lysine 4, and (iii) the heterochromatin-inducing EHMT2/G9a histone methyltransferase, which methylates histone H3 at lysine 9 (28). In contrast, others have been shown to interact with activating chromatin modifiers such as lncRNA-binding WDR5 subunit of the MLL (mixed-lineage leukemia) complex (29), which methylates histone 3 at lysine 4 (29–32). In some cases, these lncRNA-protein interactions are dictated by the structure of the lncRNA, as in the case of the stem-loop structures in some Polycomb-interacting lncRNAs (26,33). Notably, the presence of discrete structural “modules” along the length of the lncRNA can influence the binding of different protein complexes to the lncRNA, further diversifying its function [reviewed in (34)]. While it is not completely clear how lncRNAs navigate to their targets within the nucleus, it is apparent that lncRNAs can interact with transcription factors themselves (35), which could promote lncRNA targeting to discrete loci. In addition, a number of models have been proposed to describe how lncRNAs identify and interact with their targets, including sequence-based or structure-based recognition of DNA loci (24,36).

A second layer of complexity in epigenetic regulation by lncRNAs is influenced by their ability to regulate nearby loci *in cis* (32), loci far from its site of transcription *in trans* (31), or a combination of both. Interestingly, knockdown of long intergenic ncRNAs (lincRNAs) demonstrated that the majority of their regulation occurred *in trans* (37), while lncRNAs near protein-coding genes often regulate these nearby loci *in cis*, as in the case of enhancer-associated RNAs [reviewed in (38)]. Notably, a number of lncRNAs are capable of regulating nearby and distant loci and may also bind chromatin-modifying complexes with

opposing functions, suggesting that the regulatory capacity of a given lncRNA can be locus specific (39).

In addition to the well-established functions in regulating expression of discrete loci, lncRNAs also play important roles in nuclear organization and the establishment of chromosome territories. A special example of this occurs during X chromosome inactivation (XCI) in female mammalian cells, where one copy of the X chromosome is silenced to ensure proper gene dosage. Here, the *Xist* lncRNA interacts with the Polycomb repressive complex PRC2 to induce the formation of heterochromatin across the inactive X chromosome (26). Interestingly, *Xist* itself is regulated by other lncRNAs including *Tsix* and *Jpx*. *Tsix* is transcribed antisense to *Xist* and represses *Xist* expression on the active X chromosome via DNA methylation, while *Jpx* induces *Xist* transcription by sequestering a transcriptional repressor CTCF (40–42). A second well-documented example of lncRNA functioning in nuclear organization is the lncRNA *NEAT1*, which functions as an essential scaffold for the organization of RNA processing and editing “factories” called paraspeckles (43). Knockdown of *NEAT1* resulted in ablation of paraspeckles and alterations in export of mRNAs containing inverted repeats (44), suggesting an important role for this lncRNA in regulating this process.

lncRNAs in the cytoplasm

A number of lncRNAs have been demonstrated to be primarily localized within the cytoplasm or to shuttle between the nucleus and cytoplasm. These RNAs also function in diverse ways, interacting with a variety of protein-binding partners. lncRNAs have been shown to regulate protein levels (45) and function by base-pairing with the mRNA to upregulate protein translation, while some regulate mRNA degradation, recruiting proteins via the double-stranded RNA structures formed by extensive base-pairing between lncRNA and mRNA (46). Others regulate trafficking of proteins into the nucleus via their associations with the nuclear pore complex (47).

Furthermore, a growing body of evidence suggests that cytoplasmic lncRNAs can function as decoys for other ncRNAs such as miRNAs, and have been termed competing endogenous RNAs (ceRNAs) [reviewed in (48)]. While many ceRNAs function as a “sponge” to sequester miRNAs, others bind to mRNA targets and prevent miRNA-mediated downregulation (49). Interestingly, artificial ceRNAs have been utilized for more detailed characterization of miRNAs in mammalian biology [reviewed (50)].

lncRNAs regulating stem cell maintenance or differentiation

lncRNAs have also been shown to play a crucial role in maintaining pluripotency (35,37). One study (37) performed a systematic loss of function experiment in which 147 lincRNAs were knocked down in mouse embryonic stem cells (ESCs). While the differentiation capacity of these cells after lincRNA knockdown was not assessed, they observed that 93% of the lincRNAs targeted likely played an important role in maintenance of pluripotency, as their depletion resulted in gene expression profiles that were highly similar to those obtained when key pluripotency markers such as *Nanog* or *Oct4* were depleted.

A subsequent study demonstrated that lncRNAs are not only important in maintaining pluripotency, but may also act as key regulators in promoting and preserving cell identity after differentiation (35). Using a microarray chip to quantify expression of 6671 lncRNA transcripts, Ng *et al.* identified 934 differentially expressed ncRNAs as human ESCs were differentiated into neuron progenitors *in vitro*. Their functional studies focused on two classes of lncRNAs: those that were much more abundant in ESCs than in neural progenitors (NPCs) and likely played a role in maintenance of pluripotency and those that were much more abundant in NPCs than in ESCs and likely played a role in neuronal differentiation. As expected, knockdown of several lncRNAs more abundant in ESCs led to spontaneous differentiation into a variety of cell types, while knockdown of several neurogenic lncRNAs resulted in inhibition of neuronal differentiation. Functional characterization of some of these neuronal lncRNAs (e.g., *RMST*, *LINC01109*, and *CACNA2D1*) showed that they were localized to the nucleus and interacted with either the Polycomb repressive complex PRC2 or the neuronal transcription factor REST. In contrast, the neurogenic lncRNA *MIR100HG* was localized to the cytoplasm. This lncRNA also serves as a precursor to the miRNAs miR-125b and let-7 within its introns, which are known to function in neural development (51,52). Knockdown of *MIR100HG* substantially reduced the expression of these miRNAs, suggesting this lncRNA may also function as a reservoir for miRNAs important for differentiation.

Although the majority of lncRNA studies in stem cell differentiation have been carried out *in vitro*, comprehensive libraries of lncRNA expression during different stages of murine neurogenesis *in vivo* have also been described (53). In the study from Ramos *et al.*, this library was developed by integrating multiple RNA-sequencing approaches (RNA-seq and RNA CaptureSeq (54)) with assays of chromatin state using chromatin immunoprecipitation and sequencing (ChIP-seq), which provides not only a comprehensive list of expressed transcripts and splice isoforms, but also provides some indication of their regulation *in vivo*. Interestingly, comparisons of murine ESCs and micro-dissected neural stem cells (NSCs) demonstrated that many lncRNAs exhibit substantial changes in chromatin state during differentiation that correspond with transitioning from a “poised” state to an active state. For example, *lnc-pou3f2*, which is encoded upstream of the well-established neurogenic transcription factor POU3F2, is bivalently marked with both activating (H3K4me3) and repressive (H3K27me3) histone modifications in ESCs, but transitions to a fully active state marked by only H3K4me3 in NSCs. However, a substantial number of lncRNAs remain bivalently marked in NSCs, suggesting that these lncRNAs may function later during neural lineage specification. Functional validation of several lncRNAs confirmed their important roles in NSC self-renewal or differentiation, demonstrating that well-constructed lncRNA expression libraries are extremely valuable resources for investigating the roles of lncRNAs in development and disease *in vivo* across various cell types and tissues.

Other studies have demonstrated the function of lncRNAs in the definition of other cell/tissue fates, including cardiac development. The lncRNA *Fendrr* was identified by differential expression in posterior mesoderm compared to other early somite-stage mouse tissues, and *in vivo* studies in which the transcript was prematurely terminated clearly demonstrated that loss of *Fendrr* was embryonic lethal (39). Defects in both cardiac development and in development of the ventral body wall suggested defects in

differentiation of the lateral mesoderm, which was verified using gene expression analysis and chromatin profiling. Similarly, Klattenhoff and colleagues again utilized RNA-seq to identify lncRNAs that were most abundant in the murine heart compared to other tissues and identified the candidate *Braveheart (Bvht)*, a lncRNA which has no obvious homologs in human or rat tissues (55). *In vitro* studies of *Bvht* in ESC differentiation showed that this lncRNA is not required for ESC maintenance or global differentiation but plays an important role in cardiac differentiation via interactions with the Polycomb repressive complex, PRC2. Notably, these studies were possible due to the natural propensity for ESC-derived embryoid bodies to generate cardiac tissue and well-established cardiomyocyte differentiation assays, highlighting the importance of developing well-defined *in vitro* differentiation assays for other cell types of interest.

LncRNA *H19* in genomic imprinting

The highly coordinated process of genomic imprinting, in which one of two parental alleles is silenced, is a process involving lncRNAs that is of special importance to musculoskeletal biology and cancer development. One human disease associated with defective imprinting is Beckwith–Wiedemann syndrome, which results in an “overgrowth” phenotype and is caused by genetic or epigenetic changes within imprinting control regions (ICRs). These regions are regulatory loci defined by differential DNA methylation and are responsible for regulating a network of imprinted genes, including the lncRNA *H19* and insulin-like growth factor, *IGF2*; however, mutations or epigenetic changes at many other loci involved in the imprinted gene network, such as the lncRNAs *Kcnq1ot1* and *Airn*, can also confer similar phenotypes. As a result of the clear phenotypes seen with errors in imprinting and its conservation between mouse and human, the imprinted gene network involving *H19* and *IGF2* and the regulation of these loci is one of the best studied loci for genomic imprinting.

In normal circumstances, *IGF2* is expressed from the paternal allele, and the downstream lncRNA *H19* is expressed from the maternal allele. Generation of a series of genetic knockout (KO) models in mice (reviewed in (56)) revealed that genomic imprinting elements within the *H19-IGF2* locus are essential for normal imprinting and thus properly regulated *H19* and *IGF2* expression. In order for normal imprinting to occur, the zinc finger protein CTCF binds to ICRs comprised of differentially methylated regions (DMRs) and the matrix attachment region (MAR) on the maternal allele to shield the *IGF2* promoter from its enhancer. As a result, this enhancer is accessible to *H19* and promotes *H19* expression. Meanwhile on the paternal allele, methylation of the ICR blocks CTCF binding, allowing contact between the *IGF2* promoter and enhancer to promote *IGF2* expression. Simultaneously, the paternally inherited *H19* promoter is also methylated, rendering it inaccessible by both enhancers and transcription factors. In Beckwith–Wiedemann syndrome, loss or epigenetic dysfunction of an ICR typically results in either overexpression of *IGF2* or loss of the imprinted gene *CDKN1C*, which regulates cell proliferation; these phenotypes are thought to contribute to the overgrowth phenotypes observed in patients with this syndrome.

The proper regulation of *H19* and *IGF2* is critical for normal development and tissue homeostasis. During fetal development, *H19* and *IGF2* are highly expressed in endodermal

and mesodermal tissues. More importantly, their expression is tightly coordinated with identical spatial and temporal patterns (57,58), and *IGF2* utilizes fetal-specific promoters for its expression during development (59). Interestingly, in a KO mouse model in which the entire *H19* sequence was deleted, normal imprinting patterns were observed on both parental alleles (60), suggesting that *H19* does not function *in cis* to regulate *IGF2* gene expression. However, other evidence proposes that *H19* may regulate *IGF2* expression post-transcriptionally by binding to insulinlike growth factor II mRNA-binding proteins (IMPs) (61,62). *H19* can also be processed into miR-675, whose targets such as *IGFR1* and *Rb* (Retinoblastoma) are involved in cell growth and regulation (63–65).

Given that *H19* is highly abundant in the mesoderm during embryogenesis (66,67), it could be hypothesized that this lncRNA may play a role in regulating skeletal development. In the remaining sections of this review, we will focus on recent studies describing the expression and potential function of lncRNAs, including *H19*, in chondrogenesis and osteogenesis, as well as in cartilage and bone homeostasis and disease.

Cartilage Development

Cartilage is an important connective tissue that can be classified into three groups: hyaline (e.g., joint articular cartilage), elastic (e.g., ear), and fibrocartilage (e.g., meniscus and intervertebral discs in the spine). These cartilage types differ in extracellular matrix (ECM) composition and cell (chondrocyte) phenotype, thereby providing each tissue type with specific mechanical properties to carry out their function in the body.

Hyaline cartilage development is a complex process that begins with the condensation of mesenchymal stem cells (MSCs) that are derived from the mesoderm germ layer (68). In response to various signaling pathways, chondro-progenitor cells are formed. These cells proliferate and differentiate into chondrocytes that are responsible for generating the ECM which, in hyaline cartilage, consists primarily of type II collagen and the large aggregating proteoglycan, aggrecan. Two types of hyaline cartilage exist in the limb: articular cartilage and growth plate (epiphyseal) cartilage. Some controversy remains as to whether articular and growth plate cartilages are derived from common precursor cells or if the outer region of articular cartilage (i.e., the superficial zone) is derived from distinct precursor cells during synovial joint development (69,70). In any case, we know that chondrocytes of articular cartilage remain as permanent, differentiated chondrocytes that synthesize an ECM with appropriate mechanical properties to permit transmission of loads within the synovial joint during development and aging. Chondrocytes of the growth plate, however, are distinctly localized in columns where they continue to proliferate, thereby lengthening the limb during development. These cells then terminally differentiate to form large hypertrophic chondrocytes. The production of hypertrophic chondrocytes is essential to permit long bone formation via the process of endochondral ossification whereby the cartilage template is essentially replaced by bone (71). It was thought that the majority of hypertrophic chondrocytes become apoptotic during endochondral ossification, but recent studies have shown that these cells also contribute toward the osteoblast pool or that there are osteoprogenitor cells in hypertrophic cartilage that can differentiate toward bone-producing osteoblasts (72–75).

There is an abundance of knowledge with respect to the transcription factors and the signaling pathways/ mediators that regulate chondrocyte differentiation and ECM synthesis. In addition to protein-coding genes, many studies have been published on noncoding miRNAs and how their expression changes during chondrocyte differentiation (76–78) as well as how they may function in controlling chondrogenesis (79–82). In keeping with the epigenetic theme, studies are now emerging to investigate the expression and potential function of lncRNAs in cartilage development and disease.

lncRNAs regulating chondrocyte differentiation

A common method to study chondrogenesis *in vitro* involves three-dimensional culture of human mesenchymal stem/stromal cells (MSCs) isolated from bone marrow (83,84) or other sources such as adipose, synovium, and umbilical cord (85,86). A recent study utilized human bone marrow-derived MSCs (HBMSCs) to determine lncRNA expression signatures in cells 2 weeks following *in vitro* chondrogenesis compared to HBMSCs at day 0 (control) of the differentiation assay (87). Following microarray analysis (lncRNA + mRNA Human Gene Expression Microarray V4.0; CapitalBio Corp, Beijing, China), over 3000 lncRNAs were found to be significantly differentially expressed (\pm twofold) between control and chondro-induced cells. Among these, three lncRNAs were identified as upregulated following chondrogenesis (*ZBED3-AS1*, *CTA-941F9.9*, and *ENST00000433576.1*) and one was identified as downregulated (*LINC00707*; it should be noted that this lncRNA was reported as two individual genes in this report). Moreover, it is not known if these lncRNAs showed the most dramatic fold changes in this work since the entire array data was not reported. Another caveat with this study involves the relatively small increase in type II collagen expression (\sim twofold increase) after 2 weeks of chondrogenesis. Normally, *COL2A1* levels are increased by several orders of magnitude during such MSC chondrogenesis assays (88,89). Also, no *COL2A1* expression data was shown from their array study. It will be interesting to determine lncRNA expression by RNA-seq analysis in HBMSC-induced cells that produce higher levels of *COL2A1* during chondrogenesis and investigate if the same lncRNAs found in this study by Wang *et al.* are also found to be differentially expressed.

Another recent study identified that the transcription factor, SOX4, can regulate the proliferation and chondrogenic differentiation of human synovium-derived MSCs (SMSCs) and that activation of the lncRNA, *DANCR*, is involved in this process (90). Here, SMSCs were extracted from the synovium of osteoarthritis (OA) patients and aggregate cultures were utilized for *in vitro* chondrogenesis. Apparently, the differentiation medium in these assays did not include TGF- β 1/3, and so it is surprising that efficient chondrogenic differentiation was achieved. In any case, SOX4 overexpression was found to increase the expression of chondrocyte markers over 2 weeks in culture. To attempt to decipher SOX4 function in this scenario, promoter analysis of the lncRNA *DANCR* revealed a SOX4-binding site. Luciferase and CHIP assays showed that SOX4 can interact with its binding site on the *DANCR* promoter. Inhibition of *DANCR* by RNAi apparently suppressed the effects of SOX4 in promoting chondrogenesis, thereby suggesting that SOX4 functions upstream of *DANCR*. *DANCR* (Differentiation Antagonizing Non-protein Coding NA) was first described as a lncRNA (previously named *ANCR*), which functions in suppression of

progenitor cell differentiation (18). Two recent studies have shown that *DANCR* can increase stem cell-like features in hepatocellular carcinoma cells (91) and that it can suppress odontoblast-like differentiation of human dental pulp cells by inhibiting the Wnt/ β -catenin pathway (92). Given this “anti-differentiation” function, it is interesting that *DANCR* activation via *SOX4* in SMSCs resulted in increased proliferation and differentiation toward the chondrocyte lineage in this study. Further research is required to thoroughly decipher the role of *DANCR* in chondrogenesis.

With respect to human skeletal pathology, a lncRNA was recently found to be associated with brachydactyly type E (BDE), a condition characterized by shortening of metacarpals and metatarsals. In this study (93), two families with autosomal dominant BDE were identified with translocations in chromosome 12 that resulted in genomic disruption of an important cis-regulatory element named *CISTR-ACT*, which also produces the lncRNA *DA125942*. Notably, the *CISTR-ACT* locus interacted *in cis* with the *PTHLH* locus, which encodes the chondrogenic regulator parathyroid hormone-like hormone (94), and *in trans* with the *SOX9* locus, which encodes the master chondrogenic transcription factor *SOX9* (95). Importantly, knockdown of *DA125942* in a chondrogenic cell line resulted in downregulation of *PTHLH* and *SOX9*, as well as a plethora of other genes important in skeletal patterning (*HOXB* cluster, *ETV4*) or chondrogenesis (*HIF1A*), suggesting a potentially important role for this lncRNA in regulating chondrogenic differentiation.

Studies on lncRNAs associated with *HOX* genes have provided insights into their functions in regulating skeletal development. *HOX* genes are a conserved family of developmental transcription factors that elicit specific developmental programs along the head-to-tail axis of animals (96). For example, lncRNA genes in the 5' *HOXA* and *HOXD* clusters are known to regulate limb and spine growth and patterning (97–100). *HOTAIR* (HOX Transcript Antisense RNA) was the first vertebrate lncRNA described to regulate *HOX* function (31). Specifically, *HOTAIR* is expressed from the *HOXC* locus and functions to recruit EZH2 and SUZ12, part of the Polycomb repressive complex PRC2, to the *HOXD* cluster, thereby establishing a silent chromatin state using H3K27 methylation and resulting in repression of several 5' *HOXD* genes (Figure 1). Targeted deletion of *Hotair* in mice resulted in patterning malformations in the lumbosacral junction and in the metacarpal and carpal bones in the limbs (101). Interestingly, cyclic stretch has been shown to decrease *HOTAIR* levels in human aortic interstitial cells (AVICs), and reducing *HOTAIR* levels via siRNA in AVICs results in increased expression of calcification genes (102). These findings suggest that *HOTAIR* is mechanoresponsive and may thus play a potential role in mechanically regulated calcification, although additional work is needed to test this hypothesis in other cell types.

In contrast, *HOTTIP* (HOXA Transcript at the Distal Tip) is an enhancer lncRNA that regulates the expression of 5' *HOXA* genes to control the growth and elongation of skeletal elements of the limb (32). *HOTTIP* functions by regulating chromosome looping to recruit the WDR5/MLL histone methyltransferase complex to the 5' *HOXA* genes, conferring an active chromatin state via H3K4 methylation (32,103) (Figure 2B). While *HOTAIR* has been shown to act *in trans* (located on the *HOXC* locus and regulates *HOXD* genes) (Figure 1), *HOTTIP* was noted to act *in cis* (Figure 2B) and its proximity was crucial for *HOXA* gene

expression, as expression of *HOXA* genes was not changed when *HOTTIP* was ectopically expressed via lentivirus.

An elegant study published recently by Stadler's group has identified another lncRNA located within the *HOXA* locus, named *lncRNA-HIT*, which appears to function as a critical epigenetic regulator of chondrogenesis (104). *lncRNA-HIT* (HOXA Transcript Induced by TGF- β) was initially characterized as a TGF-P-responsive lncRNA during epithelial-to-mesenchymal transition in mammary epithelia (105). *lncRNA-HIT* was previously mapped as a single exon in the mouse genome between *Hoxa11* and *Hoxa13* (106). Carlson *et al.* found that *lncRNA-HIT* was expressed in the developing mouse limb and hypothesized that it may play a role in chondrogenesis. RNA FISH analysis showed that *lncRNA-HIT* is localized to the nucleus of limb mesenchymal cells, while mass spectroscopy and immunoprecipitation experiments revealed that it associates with p100/CBP complexes (Figure 2A). Knockdown of *lncRNA-HIT* in micromass cultures of murine limb mesenchymal cells was found to inhibit chondrogenesis (i.e., cartilage nodule formation) in these cultures. Further experiments in this study strongly suggest that, mechanistically, *lncRNA-HIT* functions as an enhancer lncRNA via association with p100/CBP complexes to maintain H3K27ac at specific chromatin sites thereby resulting in the activation of 5' *HoxA* genes. In addition to affecting the expression of *HoxA* genes, *lncRNA-HIT* siRNA experiments also revealed decreased expression of a number of other genes, including *Bmpr1b*. This finding may also explain why knockdown of *lncRNA-HIT* reduces cartilage formation of murine limb mesenchyme *in vitro* since loss of *Bmpr1b* is known to negatively affect chondrogenesis in mice and humans (107–110). Overall, this study is the first to provide detailed mechanistic insights into the role of a specific lncRNA in chondrogenesis and reveals another level of complexity toward our understanding of how chondrogenitor commitment and cartilage tissue development is controlled.

lncRNAs in cartilage homeostasis and osteoarthritis

OA is a painful and debilitating disease of the synovial joints that is characterized by progressive degenerative changes in the articular cartilage and other joint tissues such as the synovium and subchondral bone. Under normal circumstances, mature articular cartilage is maintained in a healthy balance of anabolic and catabolic processes by the activity of the chondrocytes. While many factors can contribute to the onset and progression of OA, disruption of cartilage homeostasis can occur if a joint is subjected to altered loading caused by malalignment or trauma (e.g., meniscal or ligament injury, articular cartilage fracture) (111–116). Obesity can also affect joint homeostasis due to increased loads as well as chronic inflammation (113,117–119). As a result, catabolism often predominates causing joint abnormalities including articular cartilage degradation, subchondral bone sclerosis, osteophyte formation, and synovitis which, collectively, can be defined as OA (120). OA is a challenging disease to treat, given that articular cartilage has little or no intrinsic regenerative capacity. Many of the cellular and molecular changes that occur in OA are known, such as alterations in growth factor and cytokine signaling, inflammation, oxidative stress, chemokine signaling, and metabolism (120–122). However, no effective therapies have yet been discovered to ameliorate or stop OA progression. It is now apparent that epigenetic modifications (e.g., DNA methylation, histone modifications) may confer

susceptibility to OA (123–132) which could open up new avenues for alternative therapeutic approaches.

To date, a small number of studies have been published on lncRNA expression and potential function in mature chondrocytes within the context of OA. The lncRNA *H19* was first reported by Dudek *et al.* to be highly expressed in mature primary articular chondrocytes and to be regulated by SOX9 (133). This study also showed that *H19* knockdown in primary chondrocytes reduced *COL2A1* levels; however, *H19* also serves as the precursor for the miRNA miR-675, and they demonstrated that the effects of *H19* knockdown could be rescued by overexpression of miR-675. Thus, they concluded that miR-675 is an important functional component of *H19* to regulate the chondrocyte phenotype.

In addition, Steck *et al.* reported that *H19* expression, as well as *IGF2*, was elevated in human OA cartilage compared to healthy, control tissue; however, *H19* and *IGF2* levels did not correlate significantly in cartilage (134). This study also showed that *H19* levels are increased in chondrocytes under hypoxic conditions, while levels decreased in response to proinflammatory cytokines. From these findings, it was speculated that *H19* may play a role in regulating chondrocyte metabolism in response to stress as well as induce chondrocyte anabolism. As will be discussed more later, *H19* was recently shown to induce osteoblast differentiation via TGF- β 1/Smad3/HDAC or β -catenin/Wnt signaling pathways (135,136). It remains to be discovered if *H19* functions in a similar manner to induce chondrogenesis. Finally, a recent report revealed a new function for *H19* in regulating DNMT3B-mediated DNA methylation (137). This is interesting from the standpoint that changes in DNA methylation patterns have been detected in human OA cartilage and that *H19* levels have been reported to be higher in OA (134,138).

A study by Kim *et al.* showed that *HOTTIP* expression was increased (assessed by microarray analysis) in chondrocytes from OA patients compared to non-OA or normal control cells (139). They also detected a decrease in *HOXA13* expression as a result of increased *HOTTIP* levels. However, it has been reported (and mentioned earlier in this review) that *HOTTIP* functions to facilitate H3K4 methylation and, therefore, activation of distal HOX genes. It is, therefore, curious that an increase in *HOTTIP* would lead to a reduced *HOXA13* expression in this study. Further mechanistic studies are needed to clarify the functional role of *HOTTIP* in regulating cartilage homeostasis.

Other microarray-based studies have been published reporting lncRNA expression changes in OA chondrocytes compared to healthy control cells (138,140,141). One of these studies reported 121 differentially expressed lncRNAs, 73 of which were significantly upregulated including *HOTAIR*, *GAS5*, *PMS2L2*, *RP11-445H22.4*, *H19*, and *CTD-2574D22.4* (138). Of these lncRNAs, *HOTAIR* and *GAS5* were also found to be upregulated in OA chondrocytes in the Kim *et al.* study mentioned above (139). The study by Liu *et al.* (141) identified 152 differentially expressed lncRNAs and focused specifically on one lncRNA (*lncRNA-CIR*; Cartilage Injury Related) which was upregulated over tenfold in OA chondrocytes, as confirmed by qPCR, and was also shown to increase in chondrocytes following treatment with IL-1 β and TNF- α . Attempts to decipher the function of *lncRNA-CIR* were done by knockdown (siRNA) and overexpression approaches; it was concluded from these

experiments that *IncRNA-CIR* can induce chondrocyte catabolic events via increased expression of MMP13 and ADAMTS-5. The study by Fu *et al.* (140) provided expression data of differentially expressed lncRNAs followed by target predictions and pathway analyses of those lncRNAs found to be most highly up- or downregulated in OA. They utilized the same microarray (Human lncRNA Array v2.0; 8×60K; Arraystar) that was used by Liu *et al.* (141) and reported many more differentially expressed lncRNAs (4714 lncRNAs) based on the fact that they included lncRNAs whose levels changed by twofold or more (as opposed to the Liu *et al.* study that reported lncRNAs with an eightfold or more change in expression).

Another recent report also showed increased expression of *GAS5* (Growth Arrest-Specific 5) in OA cartilage compared to healthy control tissue (142). RNA FISH analysis showed nuclear localization of *GAS5* in healthy chondrocytes, while localization in OA chondrocytes also revealed cytoplasmic distribution. Overexpression of *GAS5* in chondrocytes *in vitro* resulted in increased metalloproteinase expression, decreased expression of markers associated with autophagy, and decreased expression of miR-21. Manipulation of miR-21 levels in murine articular cartilage *in vivo* via lentivirus showed some degree of chondro-protection following OA-induced surgery by destabilization of the medial meniscus (DMM) (143). The overall conclusion from these findings is that *GAS5* overexpression appears to contribute to a catabolic phenotype via regulation of miR-21 in chondrocytes. Another study was published recently reporting decreased expression of the lncRNA *MEG3* (Maternally Expressed Gene 3) in OA and that its expression levels were inversely associated with *VEGF* levels (144). However, no functional data was included in this study to be able to make any conclusions on *MEG3* regulation of *VEGF* in chondrocytes.

Finally, a study recently accepted for publication by Pearson *et al.* aimed to identify lncRNAs associated with the inflammatory response in human primary hip OA chondrocytes (145). These cells were treated for 4 h with IL-1 β and differentially expressed lncRNAs between treated and untreated cells were identified following RNA-seq analysis (sequencing data is publically available via the GEO data repository: GSE74220). Of the 983 lncRNAs identified, 125 were found to be differentially expressed following IL-1 β treatment including *PACER* (p5-Associated COX2-Extragenic RNA) and two novel chondrocyte inflammation-associated lincRNAs (*CILinc01* and *CILinc02*). The increase in expression of these three lincRNAs was confirmed by additional *in vitro* assays using IL-1 β -induced primary knee or hip chondrocytes followed by qPCR analysis. Interestingly, expression of these lincRNAs was found to be lower in OA cartilage compared to healthy control tissue. This finding may be due to the fact that the inflammatory status (and hence lncRNA expression) of chondrocytes embedded within late-stage OA cartilage tissue may not correlate with that in cultured chondrocytes isolated from cartilage following treatment with IL-1 β . In any case, this report has provided in-depth information on a number of inflammatory-regulated lncRNAs that may be worth pursuing in greater detail with respect to determining their biological functions in regulating chondrocyte homeostasis.

Bone development

Unlike cartilage, bone is a rigid tissue made up mainly of collagen fibers, calcium carbonate, and hydroxyapatite. Three cell types reside within the bone tissue: osteoblasts that synthesize bone ECM, osteoclasts that resorb bone, and osteocytes that are the mechano-sensing cells embedded deep within the bone (146–148). During embryonic development, bone is formed from cells of three sources: the somites, the lateral plate mesoderm, and the cranial neural crest. Formation of bone can occur via two processes: endochondral ossification or intramembraneous ossification.

The vertebral, limb, and rib skeletons are formed by endochondral ossification that begins with the formation of a cartilage intermediate template (71). Under the control of multiple signaling pathways (e.g., BMP superfamily growth factors, FGFs, Wnts, Hedgehog), mesodermal stem cells become committed toward the chondrocyte lineage and undergo a process known as mesenchymal condensation (146). Here, the influence of cell adhesion molecules such as N-cadherin and N-CAM are noted to be highly critical in maintaining cell–cell contacts (149–151). While the master chondrocyte transcription factor Sox9 is one of the earliest markers expressed in the chondrocyte lineage, this transcription factor requires the co-activators L-Sox5 and Sox6 to fully induce the expression of other chondrogenic genes such as *Col2a1* (type II collagen) and *Acan* (aggrecan). The cells later enlarge and become hypertrophic chondrocytes that express elevated levels of *Runx2*, *Mmp13*, *Alp*, *Col10a1*, and *Vegf*. This alteration in gene expression permits the generation of an ECM that can be mineralized and vascularized (152–154). At this stage, the hypertrophic chondrocytes can become apoptotic, although as mentioned earlier in this review, recent evidence suggests that these cells, or progenitor cells within hypertrophic cartilage, can also contribute to the osteoblast pool (72–75). Following vascularization of hypertrophic cartilage, pre-osteoblasts and pre-osteoclasts infiltrate this primary center of ossification. Mature osteoblasts then function to generate new bone matrix and, at the same time, a bone marrow cavity is created. Mature osteoclasts function to resorb the trabecular bone within the ossification center. Overall, there is a critical balance between osteoblasts and osteoclasts to maintain bone homeostasis.

In contrast, intramembraneous ossification occurs when the stem cells in mesenchymal tissue differentiate directly toward the osteoblast lineage without the requirement of a cartilage template. This can be seen perhaps most clearly by the construction of our facial skeleton. Under the influence of BMPs, the cranial neural crest cells differentiate to become pre-osteoblasts which express elevated levels of *Runx2*. These cells subsequently mature into osteoblasts that can produce an osteoid matrix rich in collagen, proteoglycan, and calcium (155). There are many signaling pathways involved in intramembraneous ossification. For example, BMP, IHH (Indian Hedgehog), and PTHrP (parathyroid hormone-related protein) signaling pathways function in the commitment of cranial neural crest cells toward an osteoblast identity (155). In addition, FGF and SHH (Sonic Hedgehog) are also involved in defining the shape and size of the facial midline (156–162).

lncRNAs regulating osteoblast differentiation

To date, studies on the role of lncRNAs in bone biology have been limited. However, one report showed that homozygous mice lacking the lncRNA, *Hotair*, resulted in lumbosacral transformation and fusion of the metacarpal and carpal bones (101). This skeletal phenotype was similar to transgenic mice with ectopic expression of *HoxD* resulting in elevation and anteriorization of *Hoxd10* and *Hoxd11* expression. It has been suggested earlier that *Hotair* acts *in trans* and regulates the expression of *HoxD* genes by recruiting the Polycomb repressive complex PRC2 to the *HoxD* locus (31). RNA-seq data of WT, *Hotair*^{+/-}, and *Hotair*^{-/-} confirms the earlier hypothesis: *Hotair* deletion leads to demethylation of H3K27 and methylation of H3K4 methylation at targeted genes, resulting in derepression of *HoxD* genes. Interestingly, several imprinted loci were also identified as *Hotair* targets, including *Dlk1-Meg3* and *Igf2-H19*. Since *Hotair* and its well-known related gene *Hottip* regulate the *Hox* loci, and *Hox* genes are involved in body patterning and limb development, it was not surprising that mutation of this lncRNA led to such striking skeletal patterning defects. It will be interesting to investigate whether *Hottip* is also involved in the regulation of osteogenesis.

Recent studies have demonstrated that *H19* is upregulated during osteogenesis (135,136). Different mechanisms, which may not be exclusive of one another, have been proposed to describe *H19* function in this context. Huang and colleagues demonstrate that *H19* can function to promote osteogenesis. They showed that *H19* is processed into miR-675, which targets *TGFBI* for degradation (136) (Figure 3A). Since TGF β signaling has been previously shown to impede osteogenesis by inducing heterochromatin formation at several promoters such as *RUNX2* and *OCN* (163), a drop in TGF- β 1 would lead to derepression of these osteogenic markers and subsequently promote osteogenesis. Additionally, this study also showed that *H19*/miR-675 downregulated levels of HDAC4/5 which also resulted in increased expression of osteoblast genes, although it was not clear whether this effect is direct or indirect. Interestingly, a specific function for *H19* outside of miR-675 biogenesis was not described by Huang *et al.* In contrast, the proposed mechanism described by Liang and colleagues demonstrated that *H19* itself functions as a ceRNA, binding to miR-141 and miR-22 and sequestering them away from their mRNA targets (Figure 3B). Notably, these miRNAs were previously established to target and degrade *CTNNB1* (β -catenin) (164), and *H19* may relieve their repressive effect on the Wnt-signaling pathway by competitively binding to these miRNAs, thereby inducing osteoblast differentiation. As *H19* had previously been shown to be enriched during chondrogenesis (133), it may be the case that *H19* suppresses the stemness of MSCs in general instead of promoting specific differentiation programs in chondrogenesis and/or osteogenesis, although further evidence on the molecular mechanism of *H19* in MSCs is required to prove this hypothesis.

There have been two reports of the lncRNA *DANCR* in osteogenesis. In one study, it was proposed that *DANCR* regulates expression of the osteogenic regulator *RUNX2* by recruiting the Polycomb repressive complex component EZH2 to the *RUNX2* promoter, thereby resulting in suppression of osteogenesis (165). While RNA pulldowns showed a direct association of *DANCR* and EZH2, there was no evidence that *DANCR* was directly binding or recruiting EZH2 to directly bind to *RUNX2* promoter, which will be of interest

for future investigation. A similar study manipulated *DANCR* expression in human periodontal ligament stem cells, and also showed that downregulation of *DANCR* was critical for osteogenesis (166). Here, *DANCR* knockdown upregulated β -catenin/Wnt signaling pathway in these cells, which has been well-documented to promote osteoblastogenesis. However, this study only suggests a correlation between *DANCR* and the osteogenic markers, and no direct interactions between the lncRNA and the genomic elements regulating osteogenic genes were investigated in the study. In addition, since *DANCR* was first proposed to function as an anti-differentiation player (18–20), it might be the case that reducing *DANCR* expression evokes a global effect on the epigenetic state of the cells. Instead of directly affecting their osteogenic capability, *DANCR* may be acting to make the cells more competent for differentiation into specific cell types given the appropriate medium conditions.

Additionally, a set of lncRNA microarray expression data was also generated from a mouse MSC cell line that was stimulated with BMP2 (167). The study identified 116 lncRNAs that were differentially expressed: 59 upregulated and 57 downregulated. However, several issues were noted in this study: (i) the cut-off values used for differential expression were arbitrary and changed between time points, (ii) the experimental methods were not well-described, and (iii) data showing appropriate osteogenic induction were relatively weak. Furthermore, no functional characterization was performed to test the requirements for these lncRNAs in osteogenesis. Therefore, additional validation of differentially expressed lncRNAs in this system is still needed.

The expression of the lncRNA *HIF1A-AS1* in HBMSCs was also characterized, and the authors imply a potential role for this lncRNA in osteogenesis which is dependent on the histone deacetylase *SIRT1*, an important positive regulator of osteoblastogenesis and bone mass (168,169). Here, overexpression of *SIRT1* downregulated *HIF1a-AS1* expression, while knockdown and pharmacological inhibition of *SIRT1* upregulated *HIF1a-AS1* expression. Interestingly, *HIF1a-AS1* knockdown decreased the expression of *HOXD10*, suggesting a potential role for this lncRNA in HOX gene regulation. However, the authors describe a pro-osteogenic role for TGF- β , which has been well documented to function in an anti-osteogenic capacity. In addition, the regulation of *HIF1a-AS1* during *in vitro* osteogenic assays was not described, and it was not clear whether these experiments were performed under osteogenic conditions; so further work is needed to determine the function of this lncRNA during osteogenesis.

Last, the function of the lncRNA *MEG3* was shown to play an important role in osteogenesis, especially in the context of multiple myeloma, a hematological cancer that also affects bone mass by inhibition of osteoblastogenesis of MSCs (170). Here, it was demonstrated that *MEG3* expression increases during osteogenic differentiation of MSCs from normal patients, but its expression is reduced overall and is unchanged during osteogenesis. In normal cells, *MEG3* knockdown reduced osteogenic differentiation and functioned by reducing transcription of *BMP4*, and ectopic *MEG3* overexpression or treatment with exogenous BMP-4 rescued the osteogenic defect of MSCs from multiple myeloma patients. Mechanistically, it was shown that *MEG3* regulates *BMP4* transcription by disrupting the interaction between the SOX2 transcription factor and the *BMP4* promoter.

Interestingly, overexpression of *MEG3* in MSCs from multiple myeloma patients also improved chondrogenic differentiation, suggesting a potential role for this lncRNA in chondrocyte differentiation as well.

lncRNAs in osteosarcoma

Osteosarcoma is a type of bone cancer that occurs at a rate of 5% in pediatric malignancies (171,172). In humans, osteoblastic osteosarcoma is characterized by highly mineralized tissues that are abundant in osteoids with multinucleated cells (173,174). From recent improvements in surgical, therapeutic, and radiation care, the survival rate of osteosarcoma patients has increased from less than 20–70% over the past 40 years (175–179). However, elucidation of the molecular basis of disease development and progression is required to establish better treatment options. Recently, several lncRNAs have been identified that show differential expression in osteosarcoma tissue.

One lncRNA that is dysregulated in osteosarcoma is *MALAT-1* (Metastasis-Associated Lung Adenocarcinoma Transcript 1), a 6.8kb transcript that is conserved among 33 mammalian species (180). Unlike most lncRNA, *MALAT-1* is not poly-adenylated at its 3' end but instead folds into a triple helix (Figure 4), a unique structure that protects the RNA from degradation by nucleases (181). *MALAT-1* is expressed in many types of cancers, where it often promotes proliferation [reviewed in (182)]. Therefore, it is not surprising that *MALAT-1* was also observed to be upregulated in osteosarcoma (183,184). These independent studies established that knockdown of *MALAT-1* in osteosarcoma cells not only decreased proliferation but also induced apoptosis, and knockdown reduced osteosarcoma growth and metastasis *in vivo*. In addition, a third study utilizing the MG63 osteosarcoma cell line demonstrated that *MALAT-1* was downregulated by high-dose estrogen, and this downregulation reduced proliferation, migration, and invasion (185). *MALAT-1* appeared to sequester the splicing complex factor SFPQ from its splicing co-regulator PTBP2 (Figure 4), and downregulation of *MALAT-1* resulted in a higher accumulation of the SFPQ/PTBP2 complex. Interestingly, similar results have been observed in colon cancer cells, in which sequestration of SFPQ by *MALAT-1* results in PTBP2-mediated increases in cellular proliferation and migration (186).

Many lncRNAs have been identified using similar methods, and *in vitro* studies show that they may play important roles in osteosarcoma. Much like *MALAT-1*, the lncRNA *SNHG12* (Small Nucleolar RNA Host Gene 12) is upregulated in osteosarcoma patients (187,188). Both studies demonstrated that expression of *SNHG12* correlated with expression of *AMOT* (angiominin), a gene with unknown functions in osteosarcoma. While modulation of *SNHG12* substantially altered expression of *AMOT*, the mechanism of regulation is not clear, and the function of this lncRNA and *AMOT* has not been clearly established (187). Similarly, the lncRNA *HULC* (Highly Upregulated in Liver Cancer) is upregulated in osteosarcoma tissues (189), and knockdown of *HULC* in osteosarcoma cell lines *in vitro* suppressed proliferation, migration, and invasion. In contrast, the lncRNA *TUSC7* (Tumor Suppressor Candidate 7), also known as *LOC285194*, is substantially downregulated in osteosarcoma, and low expression of this lncRNA correlates with poor survival in osteosarcoma patients (190,191). Interestingly, expression changes in this lncRNA seemed

to correlate with copy number alterations rather than an epigenetic silencing of the genes. In contrast to *MALAT-1*, knockdown of *TUSC7* or *LOC285194* led to increased proliferation and/or decreased apoptosis, and *in vivo* xenograft studies showed that *TUSC7* silencing promoted tumor growth. Last, the promoter-upstream transcript *HIF2PUT* has been proposed to regulate expression of *HIF2A* in osteosarcoma (192). While the expression of *HIF2PUT* and *HIF2A* in osteosarcoma appeared to be relatively weakly correlated, knockdown of *HIF2PUT* increased cell proliferation and invasion *in vitro* in an osteosarcoma cell line, suggesting that this class of lncRNAs may also function in osteosarcoma.

In addition, lncRNAs that function in chondrocyte or osteoblast differentiation and homeostasis have also been found to be dysregulated in osteosarcoma, including *DANCR*, *PACER*, *HOTAIR*, *HOTTIP*, and *H19*. Much like *MALAT-1*, knockdown of *DANCR* in osteosarcoma cell lines reduced cell proliferation and resulted in cell cycle arrest (193). Similarly, the lncRNAs *PACER*, *HOTAIR*, and *HOTTIP* were shown to be upregulated in osteosarcoma, and knockdown of these lncRNAs inhibited proliferation and/or invasion of osteosarcoma cells (194–196). Mechanistic investigation of *PACER* function demonstrated that it upregulates the expression of the oncogene *COX2* in an NF- κ B-dependent manner. A role for *H19* in osteosarcoma has been proposed by Chan and colleagues, who developed a model for spontaneous development of osteoblastic osteosarcoma in which *p53*-heterozygous mice containing an osteoblast-specific inactivation of *Patch1* results in partial upregulation of Hedgehog signaling (173). In this model, the Hippo pathway transcriptional coactivator yes-associated protein 1 (Yap1) was upregulated by Hedgehog signaling, and in turn upregulates *H19*. Interestingly, loss of imprinting at the *H19-IGF2* has previously been observed in osteosarcoma (197), suggesting a potential function for *H19* and genomic imprinting in this setting.

Finally, other clinical investigations have revealed correlations between lncRNA expression levels and osteosarcoma patient survival. Decreased expression of *MEG3* (198) and upregulation of *TUG1* (Taurine-Upregulated Gene 1) (199) correlate strongly with poor prognosis in osteosarcoma, while the lncRNA *ODRUL* (Osteosarcoma Doxorubicin-Resistance Upregulated lncRNA) correlates strongly with poor response to doxorubicin chemotherapy (200). These preliminary data suggested that we may eventually be able to utilize lncRNAs as predictive biomarkers.

Characterization of lncRNAs

The field of lncRNA biology is relatively young by scientific standards, and significant investments are still being made to identify new lncRNAs across different tissues and among species. Many techniques that have been utilized to study well-characterized lncRNAs for some time will continue to be used to interrogate the functions of these newly identified lncRNAs. However, advances in other areas such as next-generation sequencing have improved our ability to characterize lncRNAs and have drastically improved assay throughput. Various approaches being utilized to determine lncRNA localization and function will be discussed in this section.

Identification of novel lncRNAs

While protein-coding genes can be predicted computationally from genomic sequences by virtue of their coding capacity and high levels of conservation, the identification of new lncRNAs cannot be performed in this manner, as noncoding transcripts lack these features. Notably, although comparisons of known lncRNAs demonstrated some degree of positive selection and conservation of secondary structure (201–203), predictive algorithms have a high false-positive rate for identification of new lncRNAs (204, 205). Furthermore, some well-characterized lncRNAs such as *HOTAIR* show highly divergent sequences and gene structures across species and are missed by these predictions, yet the function appears to be conserved (101).

As a result of this and significant advances in sequencing-based technologies and analysis pipelines, RNA sequencing (RNA-seq) experiments remain the gold standard for identification of lncRNAs and have been implemented to identify novel lncRNAs across a variety of tissues and species. While sufficient depth of sequencing (100–200 million reads) is a critical parameter for high-quality studies seeking to exhaustively identify novel low-abundance lncRNAs in a given tissue (206), lower-coverage experiments such as those utilized by Iyer and colleagues (207) can be pooled together to facilitate preliminary identification of novel transcripts. Identification of novel lncRNAs from RNA-seq datasets typically relies on analytical pipelines such as TopHat, which aligns reads that may contain splice junctions to the genome, and Cufflinks, which assembles transcripts *de novo* using these alignments (208,209).

In addition to these first-pass strategies for identification of novel lncRNAs, additional methods are typically used to define the ends of the transcript and to validate the presence of additional splice isoforms. In many cases, these methods have been updated such that high-throughput sequencing-based methods may be used. While isoforms for a single gene can be identified from cDNA by PCR, detailed interrogation of many loci of interest can be accomplished utilizing protocols such as Capture-Seq, which enrich for sequences of interest using hybridization-based methods and significantly reduce the required depth of sequencing for identification of novel transcripts (54). In addition, identification of the 5' end of the transcript, which is often underrepresented in sequencing libraries, using rapid amplification of cDNA ends (RACE) can be parallelized using methods like Deep-RACE (210).

Identifying clues to lncRNA function

Perhaps the most telling indicator of lncRNA function is its subcellular localization, as this provides insight into its potential binding partners and signals its capacity for re-wiring gene regulation at the transcriptional or post-transcriptional levels. A prominent method for lncRNA localization is single-molecule RNA *in situ* hybridization. When combined with fluorescence microscopy, these techniques can provide information relating to not only whether the lncRNA is nuclear or cytoplasmic, but whether it is present near putative mRNA or genomic targets within the cell (211). Furthermore, this methodology can also allow one to estimate the range of expression among single cells, and as a result, to more rigorously quantify the lncRNA of interest (212). Other methods relying on cellular fractionation can

yield additional complementary information regarding lncRNA function. While the functions of ribosome-associated lncRNAs are not yet clear, ribosome profiling and ribosome fractionation experiments identified a number of ribosome-associated lncRNAs (213), and nuclear fractionation studies revealed a large number of lncRNAs associated to actively transcribed chromatin (214).

Identification of the DNA, RNA, and/or proteins that interact with a given lncRNA generates a second tier of information regarding its function (215). Unbiased approaches to identify these partners often rely on hybridization-based methods to isolate the lncRNA and its binding partners from the cell. Subsequently, next-generation sequencing can be used to identify interactions between other RNA molecules using RNA antisense purification (RAP-seq; (216)), chromatin domains using chromatin isolation by RNA purification (ChIRP; (217)) or capture hybridization analysis of RNA targets (CHART; (218)), or proteins using a wide range of RNA pulldown techniques coupled to mass spectrometry [RAP-MS; (219); Csy4 nuclease coupled by MS; (220)]. Notably, more direct interrogation of the functions of nuclear lncRNAs in regulation of individual loci is now possible with the development of the CRISPR-Display technique (221). This technique uses locus-specific guide RNAs to target a Cas9-lncRNA complex to the desired genomic location, which not only facilitates the detailed characterization of the lncRNA on the locus of interest, but also allows the identification of specific features within the lncRNA that are required for its function.

A third powerful predictor of lncRNA function is the secondary and tertiary structure of the transcript. For example, stem-loop structures are frequently present in ncRNAs that interact with the Polycomb complex protein PRC2, a key epigenetic regulator (33). As mentioned previously, a variety of methods are available to predict RNA secondary structure (202,203,222). However, more rigorous experimental analysis of RNA secondary and tertiary structure is frequently performed using chemical and enzymatic probes. Much like the previously described methods, these methods have been recently adapted to be compatible with next-generation sequencing technologies, yielding techniques like Structure-seq, SHAPE-seq, and FragSeq (223–225).

Finally, while RNA-seq is a powerful technique for identifying new lncRNAs, it also proves useful in predicting potential functions of lncRNAs *in vivo* through the identification of co-regulated gene networks. By identifying mRNAs that are regulated similarly to the lncRNAs of interest in response to developmental or environmental stimuli, a network of genes affecting specific pathways can be developed and tested using these techniques (226).

Validation of lncRNA function through reverse genetics

Probing the functions of lncRNAs using reverse genetics *in vivo* is complex, but a number of techniques can be used easily *in vitro* and *in vivo*. Antisense knockdown of lncRNAs has become commonplace, and techniques exist for robust knockdown of both nuclear and cytoplasmic lncRNAs (227,228). Furthermore, *in vivo* electroporation of short hairpin RNAs (shRNAs) to knockdown lncRNAs have also been used to target the *Miat* lncRNA, suggesting that this may be a relatively useful tool for characterizing lncRNA function. However, strategies relying on RNA interference may be limited by delivery of the siRNA or

shRNA, low knockdown efficiency, and off-target effects, and the importance of including well-designed experimental controls can complicate the design of *in vivo* studies.

The utility of KO animal models for protein-coding genes has been essential for thorough investigations of their functions, but the design of similar models for lncRNAs is much more challenging. Exon-deletion strategies and the use of CRISPR-Cas technologies to introduce frameshifts in protein-coding genes have been very successful (229), but these are likely much less effective for lncRNAs, as there is no ORF to be altered and a lncRNA may retain its function even if significant regions are deleted (21,230–232). Furthermore, as the entire genomic region encoding the lncRNA needs to be removed in order to generate a true null mutant, it is especially important to ensure that regulatory regions that may be encoded within the locus are not perturbed.

Despite these challenges, a number of KO animal models have been developed for lncRNAs and have been reviewed elsewhere (233). In addition, a number of lncRNAs have been modeled successfully by a variety of genetic manipulations including gene disruptions [*Xist*; (234)], targeted promoter deletions [*Kcnq1ot1*; (235)], premature termination strategies [*Kcnq1ot1*; (28)], and the previously mentioned *in vivo* knockdown strategies [*Miat*; (236)]. Thus, as with other genetic models in cell culture and *in vivo*, recent advances in CRISPR-Cas technologies, especially those improving efficiency of targeted knock-in strategies, will likely improve the speed at which lncRNA targeting studies can be accomplished (237).

Conclusions and future studies

Although the half-lives of lncRNAs are, in general, less than those of mRNA (238), they are being recognized as potentially important biomarkers for a number of diseases, particularly cancers (239). For example, one of the most specific biomarkers for human prostate cancer identified to date is the lncRNA, *PCA3* (prostate cancer antigen 3) (240,241). Circulating lncRNAs have been detected in whole blood, plasma, serum, and urine and have also recently been proposed as biomarkers for diseases such as gastric cancer and heart failure (242,243). lncRNAs have also been found in extracellular vesicles (i.e., exosomes), which likely increases their half-life *in vivo*, and thus their potential as a biomarker (244–246). In this regard, lncRNAs could potentially serve as a biomarker of OA or repair processes in the joint, although to date, little is known regarding the relationship between lncRNAs and OA severity. Similarly, future studies will inform us of whether or not lncRNAs could be used as predictive or prognostic biomarkers of bone diseases such as osteoporosis.

Given the size and cellular location of lncRNAs, challenges exist to attempt to knockdown or overexpress these ncRNAs as a means to treat disease. However, we can employ the knowledge acquired from manipulating protein-coding gene expression. In this regard, there are various ways to alter the expression of lncRNAs, including the use of viral or non-viral vectors, RNA-based or genome-editing approaches. While there have been approximately 1800 approved gene therapies in clinical trials from 1989 to 2012 (247), viral-based vectors face major limitations, most notably insertional mutagenesis and immunogenicity. For this reason, the use of non-viral vectors is an attractive alternative. While typical delivery systems (such as lipofectamine or polyethyleneimine) are associated with low efficiency and

cytotoxicity (248,249), recent advances have presented the field with new improvements, such as chitosan for non-viral gene delivery that is both efficient and non-toxic (250). In addition, other methods to alter gene expression have also been explored. In the field of RNA therapeutics, it was demonstrated that higher potency and lower dose administration can be achieved with engineered antisense oligonucleotides, such as locked nucleic acid (LNA)-based gapmers (251), multimers, or multi-targeting oligonucleotides (252). Finally, lncRNA expression can potentially be controlled with modified CRISPR–Cas9 complexes. CRISPR (Clustered Regularly Interspaced Palindromic Repeats) and its associated nuclease Cas9 is a powerful and breakthrough genome editing tool. One of the many uses of CRISPR–Cas9 is knocking out protein-coding genes, mainly by introducing frame-shift mutations. However, the system is posed with difficulty when it comes to knocking out lncRNAs due to their lack of an ORF. Nevertheless, this can be achieved by establishing dual cuts to remove the entire gene fragment (237). Alternatively, modified CRISPR-dCas9 systems can also be exploited to enhance or reduce lncRNA expression. A derivative of Cas9, dCas9 is engineered to be nuclease deficient, and can be fused with various effectors to achieve desired transcriptional control. This includes, but not limited to, dCas9-KRAB (253,254) for gene repression and dCas9-VP48 (255), dCas9-VP64 (256) (257), dCas9-p300 (258), dCas9-VP64/p65 (259) for gene activation.

Clearly, lncRNAs play significant roles in regulating cellular fate and function, and in many cases, their dysregulation is associated with disease. With respect to chondrogenesis and osteogenesis, research on how lncRNAs regulate differentiation of stem/progenitor cells toward the chondrocyte or osteoblast lineage is still in its infancy. We predict that research interests in this area will significantly increase over the coming years and provide us with important knowledge on new players involved in the regulation of cartilage and bone development. Similarly, nothing is known yet on how lncRNAs could potentially control homeostasis of mature cartilage or bone; such discoveries will have a profound impact on understanding skeletal diseases such as OA and osteoporosis, and in determining new therapeutic strategies to treat these conditions. Given the size and cellular location of lncRNAs, challenges exist to attempt to knockdown or overexpress these ncRNAs as a means to treat disease. However, through advancing technologies, it is anticipated that novel, effective approaches to modulate lncRNA expression or function *in vivo* will soon be discovered.

References

1. Kapranov P, Willingham AT, Gingeras TR. Genome-wide transcription and the implications for genomic organization. *Nat Rev Genet.* 2007; 8(6):413–423. [PubMed: 17486121]
2. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. *Nat Rev Genet.* 2009; 10(3):155–159. [PubMed: 19188922]
3. Aravin A, Gaidatzis D, Pfeffer S, Lagos-Quintana M, Landgraf P, Iovino N, Morris P, Brownstein MJ, Kuramochi-Miyagawa S, Nakano T, Chien M, Russo JJ, Ju J, Sheridan R, Sander C, Zavolan M, Tuschl T. A novel class of small RNAs bind to MILI protein in mouse testes. *Nature.* 2006; 442(7099):203–207. [PubMed: 16751777]
4. Grishok A, Mello CC. RNAi (Nematodes: *Caenorhabditis elegans*). *Adv Genet.* 2002; 46:339–360. [PubMed: 11931230]
5. Montgomery MK, Fire A. Double-stranded RNA as a mediator in sequence-specific genetic silencing and cosuppression. *Trends Genet.* 1998; 14(7):255–258. [PubMed: 9676523]

6. Ambros V. microRNAs: tiny regulators with great potential. *Cell*. 2001; 107(7):823–826. [PubMed: 11779458]
7. Amaral PP, Mattick JS. Noncoding RNA in development. *Mamm Genome*. 2008; 19(7–8):454–492. [PubMed: 18839252]
8. Girard A, Sachidanandam R, Hannon GJ, Carmell MA. A germline-specific class of small RNAs binds mammalian Piwi proteins. *Nature*. 2006; 442(7099):199–202. [PubMed: 16751776]
9. Grivna ST, Beyret E, Wang Z, Lin H. A novel class of small RNAs in mouse spermatogenic cells. *Genes Dev*. 2006; 20(13):1709–1714. [PubMed: 16766680]
10. Lau NC, Seto AG, Kim J, Kuramochi-Miyagawa S, Nakano T, Bartel DP, Kingston RE. Characterization of the piRNA complex from rat testes. *Science*. 2006; 313(5785):363–367. [PubMed: 16778019]
11. Lee HC, Chang SS, Choudhary S, Aalto AP, Maiti M, Bamford DH, Liu Y. qiRNA is a new type of small interfering RNA induced by DNA damage. *Nature*. 2009; 459(7244):274–277. [PubMed: 19444217]
12. Vagin VV, Sigova A, Li C, Seitz H, Gvozdev V, Zamore PD. A distinct small RNA pathway silences selfish genetic elements in the germline. *Science*. 2006; 313(5785):320–324. [PubMed: 16809489]
13. Watanabe T, Takeda A, Tsukiyama T, Mise K, Okuno T, Sasaki H, Minami N, Imai H. Identification and characterization of two novel classes of small RNAs in the mouse germline: retrotransposon-derived siRNAs in oocytes and germline small RNAs in testes. *Genes Dev*. 2006; 20(13):1732–1743. [PubMed: 16766679]
14. Cunningham F, Amode MR, Barrell D, Beal K, Billis K, Brent S, Carvalho-Silva D, Clapham P, Coates G, Fitzgerald S, Gil L, Girón CG, Gordon L, Hourlier T, Hunt SE, Janacek SH, Johnson N, Juettemann T, Kähäri AK, Keenan S, Martin FJ, Maurel T, McLaren W, Murphy DN, Nag R, Overduin B, Parker A, Patricio M, Perry E, Pignatelli M, Riat HS, Sheppard D, Taylor K, Thormann A, Vullo A, Wilder SP, Zadissa A, Aken BL, Birney E, Harrow J, Kinsella R, Muffato M, Ruffier M, Searle SMJ, Spudich G, Trevanion SJ, Yates A, Zerbino DR, Flicek P. Ensembl 2015. *Nucleic Acids Res*. 2015; 43(Database issue):D662–D669. [PubMed: 25352552]
15. Wright MW. A short guide to long non-coding RNA gene nomenclature. *Hum Genomics*. 2014; 8:7. [PubMed: 24716852]
16. Brockdorff N, Ashworth A, Kay GF, Cooper P, Smith S, McCabe VM, Norris DP, Penny GD, Patel D, Rastan S. Conservation of position and exclusive expression of mouse Xist from the inactive X chromosome. *Nature*. 1991; 351(6324):329–331. [PubMed: 2034279]
17. Brown CJ, Ballabio A, Rupert JL, Lafreniere RG, Grompe M, Tonlorenzi R, Willard HF. A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. *Nature*. 1991; 349(6304):38–44. [PubMed: 1985261]
18. Kretz M, Webster DE, Flockhart RJ, Lee CS, Zehnder A, Lopez-Pajares V, Qu K, Zheng GX, Chow J, Kim GE, Rinn JL, Chang HY, Siprashvili Z, Khavari PA. Suppression of progenitor differentiation requires the long noncoding RNA ANCR. *Genes Dev*. 2012; 26(4):338–343. [PubMed: 22302877]
19. Nagase T, Miyajima N, Tanaka A, Sazuka T, Seki N, Sato S, Tabata S, Ishikawa K, Kawarabayasi Y, Kotani H, Nomura N. Prediction of the coding sequences of unidentified human genes III. The coding sequences of 40 new genes (KIAA0081-KIAA0120) deduced by analysis of cDNA clones from human cell line KG-1. *DNA Res*. 1995; 2(1):37–43. [PubMed: 7788527]
20. Kikuchi K, Fukuda M, Ito T, Inoue M, Yokoi T, Chiku S, Mitsuyama T, Asai K, Hirose T, Aizawa Y. Transcripts of unknown function in multiple-signaling pathways involved in human stem cell differentiation. *Nucleic Acids Res*. 2009; 37(15):4987–5000. [PubMed: 19531736]
21. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG, Lagarde J, Veeravalli L, Ruan X, Ruan Y, Lassmann T, Carninci P, Brown JB, Lipovich L, Gonzalez JM, Thomas M, Davis CA, Shiekhatter R, Gingeras TR, Hubbard TJ, Notredame C, Harrow J, Guigo R. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. *Genome Res*. 2012; 22(9):1775–1789. [PubMed: 22955988]

22. Mattick JS, Rinn JL. Discovery and annotation of long noncoding RNAs. *Nat Struct Mol Biol.* 2015; 22(1):5–7. [PubMed: 25565026]
23. Geisler S, Collier J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. *Nat Rev Mol Cell Biol.* 2013; 14(11):699–712. [PubMed: 24105322]
24. Chu C, Qu K, Zhong FL, Artandi SE, Chang HY. Genomic maps of long noncoding RNA occupancy reveal principles of RNA-chromatin interactions. *Mol Cell.* 2011; 44(4):667–678. [PubMed: 21963238]
25. Khalil AS, Ferrer JM, Brau RR, Kottmann ST, Noren CJ, Lang MJ, Belcher AM. Single M13 bacteriophage tethering and stretching. *Proceedings of the National Academy of Sciences of the United States of America.* 2007; 104(12):4892–4897. [PubMed: 17360403]
26. Zhao J, Sun BK, Erwin JA, Song JJ, Lee JT. Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome. *Science.* 2008; 322(5902):750–756. [PubMed: 18974356]
27. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, Shi Y, Segal E, Chang HY. Long noncoding RNA as modular scaffold of histone modification complexes. *Science.* 2010; 329(5992):689–693. [PubMed: 20616235]
28. Mancini-Dinardo D, Steele SJ, Levorse JM, Ingram RS, Tilghman SM. Elongation of the *Kcnq1ot1* transcript is required for genomic imprinting of neighboring genes. *Genes Dev.* 2006; 20(10):1268–1282. [PubMed: 16702402]
29. Yang YW, Flynn RA, Chen Y, Qu K, Wan B, Wang KC, Lei M, Chang HY. Essential role of lncRNA binding for WDR5 maintenance of active chromatin and embryonic stem cell pluripotency. *Elife.* 2014; 3:e02046. [PubMed: 24521543]
30. Gomez JA, Wapinski OL, Yang YW, Bureau JF, Gopinath S, Monack DM, Chang HY, Brahic M, Kirkegaard K. The NeST long ncRNA controls microbial susceptibility and epigenetic activation of the interferon-gamma locus. *Cell.* 2013; 152(4):743–754. [PubMed: 23415224]
31. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Bruggmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E, Chang HY. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. *Cell.* 2007; 129(7):1311–1323. [PubMed: 17604720]
32. Wang KC, Yang YW, Liu B, Sanyal A, Corces-Zimmerman R, Chen Y, Lajoie BR, Protacio A, Flynn RA, Gupta RA, Wysocka J, Lei M, Dekker J, Helms JA, Chang HY. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. *Nature.* 2011; 472(7341):120–124. [PubMed: 21423168]
33. Kanhere A, Viiri K, Araujo CC, Rasaiyaah J, Bouwman RD, Whyte WA, Pereira CF, Brookes E, Walker K, Bell GW, Pombo A, Fisher AG, Young RA, Jenner RG. Short RNAs are transcribed from repressed polycomb target genes and interact with polycomb repressive complex-2. *Mol Cell.* 2010; 38(5):675–688. [PubMed: 20542000]
34. Mercer TR, Mattick JS. Structure and function of long noncoding RNAs in epigenetic regulation. *Nat Struct Mol Biol.* 2013; 20(3):300–307. [PubMed: 23463315]
35. Ng SY, Johnson R, Stanton LW. Human long non-coding RNAs promote pluripotency and neuronal differentiation by association with chromatin modifiers and transcription factors. *EMBO J.* 2012; 31(3):522–533. [PubMed: 22193719]
36. Schmitz KM, Mayer C, Postepska A, Grummt I. Interaction of noncoding RNA with the rDNA promoter mediates recruitment of DNMT3b and silencing of rRNA genes. *Genes Dev.* 2010; 24(20):2264–2269. [PubMed: 20952535]
37. Guttman M, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G, Young G, Lucas AB, Ach R, Bruhn L, Yang X, Amit I, Meissner A, Regev A, Rinn JL, Root DE, Lander ES. lincRNAs act in the circuitry controlling pluripotency and differentiation. *Nature.* 2011; 477(7364):295–300. [PubMed: 21874018]
38. Lam MT, Li W, Rosenfeld MG, Glass CK. Enhancer RNAs and regulated transcriptional programs. *Trends Biochem Sci.* 2014; 39(4):170–182. [PubMed: 24674738]
39. Grote P, Witterl L, Hendrix D, Koch F, Wahrisch S, Beisaw A, Macura K, Blass G, Kellis M, Werber M, Herrmann BG. The tissue-specific lncRNA *Fendrr* is an essential regulator of heart and body wall development in the mouse. *Dev Cell.* 2013; 24(2):206–214. [PubMed: 23369715]
40. Sado T, Hoki Y, Sasaki H. Tsix silences Xist through modification of chromatin structure. *Dev Cell.* 2005; 9(1):159–165. [PubMed: 15992549]

41. Sun S, Del Rosario BC, Szanto A, Ogawa Y, Jeon Y, Lee JT. Jpx RNA activates Xist by evicting CTCF. *Cell*. 2013; 153(7):1537–1551. [PubMed: 23791181]
42. Tian D, Sun S, Lee JT. The long noncoding RNA, Jpx, is a molecular switch for X chromosome inactivation. *Cell*. 2010; 143(3):390–403. [PubMed: 21029862]
43. Clemson CM, Hutchinson JN, Sara SA, Ensminger AW, Fox AH, Chess A, Lawrence JB. An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. *Mol Cell*. 2009; 33(6):717–726. [PubMed: 19217333]
44. Chen LL, Carmichael GG. Altered nuclear retention of mRNAs containing inverted repeats in human embryonic stem cells: functional role of a nuclear noncoding RNA. *Mol Cell*. 2009; 35(4):467–478. [PubMed: 19716791]
45. Carrieri C, Cimatti L, Biagioli M, Beugnet A, Zucchelli S, Fedele S, Pesce E, Ferrer I, Collavin L, Santoro C, Forrest AR, Carninci P, Biffo S, Stupka E, Gustincich S. Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat. *Nature*. 2012; 491(7424):454–457. [PubMed: 23064229]
46. Gong C, Maquat LE. lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3' UTRs via Alu elements. *Nature*. 2011; 470(7333):284–288. [PubMed: 21307942]
47. Willingham AT, Orth AP, Batalov S, Peters EC, Wen BG, Aza-Blanc P, Hogenesch JB, Schultz PG. A strategy for probing the function of noncoding RNAs finds a repressor of NFAT. *Science*. 2005; 309(5740):1570–1573. [PubMed: 16141075]
48. Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. *Nature*. 2014; 505(7483):344–352. [PubMed: 24429633]
49. Faghihi MA, Zhang M, Huang J, Modarresi F, Van der Brug MP, Nalls MA, Cookson MR, St-Laurent G 3rd, Wahlestedt C. Evidence for natural antisense transcript-mediated inhibition of microRNA function. *Genome Biol*. 2010; 11(5):R56. [PubMed: 20507594]
50. Brown BD, Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. *Nature Rev Genet*. 2009; 10(8):578–585. [PubMed: 19609263]
51. Le MT, Xie H, Zhou B, Chia PH, Rizk P, Um M, Udolph G, Yang H, Lim B, Lodish HF. MicroRNA-125b promotes neuronal differentiation in human cells by repressing multiple targets. *Mol Cell Biol*. 2009; 29(19):5290–5305. [PubMed: 19635812]
52. Rybak A, Fuchs H, Smirnova L, Brandt C, Pohl EE, Nitsch R, Wolczyn FG. A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. *Nat Cell Biol*. 2008; 10(8):987–993. [PubMed: 18604195]
53. Ramos AD, Diaz A, Nellore A, Delgado RN, Park KY, Gonzales-Roybal G, Oldham MC, Song JS, Lim DA. Integration of genome-wide approaches identifies lncRNAs of adult neural stem cells and their progeny in vivo. *Cell Stem Cell*. 2013; 12(5):616–628. [PubMed: 23583100]
54. Mercer TR, Gerhardt DJ, Dinger ME, Crawford J, Trapnell C, Jeddloh JA, Mattick JS, Rinn JL. Targeted RNA sequencing reveals the deep complexity of the human transcriptome. *Nat Biotechnol*. 2012; 30(1):99–104.
55. Klattenhoff CA, Scheuermann JC, Surface LE, Bradley RK, Fields PA, Steinhäuser ML, Ding H, Butty VL, Torrey L, Haas S, Abo R, Tabebordbar M, Lee RT, Burge CB, Boyer LA. Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. *Cell*. 2013; 152(3):570–583. [PubMed: 23352431]
56. Arney KL. H19 and Igf2-enhancing the confusion? *Trends Genet*. 2003; 19(1):17–23. [PubMed: 12493244]
57. Gabory A, Ripoché MA, Yoshimizu T, Dandolo L. The H19 gene: regulation and function of a non-coding RNA. *Cytogenet Genome Res*. 2006; 113(1–4):188–193. [PubMed: 16575179]
58. Ohlsson R, Hedborg F, Holmgren L, Walsh C, Ekstrom TJ. Overlapping patterns of IGF2 and H19 expression during human development: biallelic IGF2 expression correlates with a lack of H19 expression. *Development*. 1994; 120(2):361–368. [PubMed: 8149914]
59. Taniguchi T, Schofield AE, Scarlett JL, Morison IM, Sullivan MJ, Reeve AE. Altered specificity of IGF2 promoter imprinting during fetal development and onset of Wilms tumour. *Oncogene*. 1995; 11(4):751–756. [PubMed: 7651739]

60. Ripoche MA, Kress C, Poirier F, Dandolo L. Deletion of the H19 transcription unit reveals the existence of a putative imprinting control element. *Genes Dev.* 1997; 11(12):1596–1604. [PubMed: 9203585]
61. Hansen TV, Hammer NA, Nielsen J, Madsen M, Dalbaeck C, Wewer UM, Christiansen J, Nielsen FC. Dwarfism and impaired gut development in insulinlike growth factor II mRNA-binding protein 1-deficient mice. *Mol Cell Biol.* 2004; 24(10):4448–4464. [PubMed: 15121863]
62. Runge S, Nielsen FC, Nielsen J, Lykke-Andersen J, Wewer UM, Christiansen J. H19 RNA binds four molecules of insulin-like growth factor II mRNA-binding protein. *J Biol Chem.* 2000; 275(38):29562–29569. [PubMed: 10875929]
63. Tsang WP, Ng EK, Ng SS, Jin H, Yu J, Sung JJ, Kwok TT. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. *Carcinogenesis.* 2010; 31(3):350–358. [PubMed: 19926638]
64. Keniry A, Oxley D, Monnier P, Kyba M, Dandolo L, Smits G, Reik W. The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. *Nat Cell Biol.* 2012; 14(7):659–665. [PubMed: 22684254]
65. Cai X, Cullen BR. The imprinted H19 noncoding RNA is a primary microRNA precursor. *Rna.* 2007; 13(3):313–316. [PubMed: 17237358]
66. Lustig O, Ariel I, Ilan J, Lev-Lehman E, De-Groot N, Hochberg A. Expression of the imprinted gene H19 in the human fetus. *Mol Reprod Dev.* 1994; 38(3):239–246. [PubMed: 7917273]
67. Poirier F, Chan CT, Timmons PM, Robertson EJ, Evans MJ, Rigby PW. The murine H19 gene is activated during embryonic stem cell differentiation in vitro and at the time of implantation in the developing embryo. *Development.* 1991; 113(4):1105–1114. [PubMed: 1811930]
68. Hall BK, Miyake T. The membranous skeleton: the role of cell condensations in vertebrate skeletogenesis. *Anat Embryol (Berl).* 1992; 186(2):107–124. [PubMed: 1510240]
69. Hyde G, Dover S, Aszodi A, Wallis GA, Boot-Handford RP. Lineage tracing using matrilin-1 gene expression reveals that articular chondrocytes exist as the joint interzone forms. *Dev Biol.* 2007; 304(2):825–833. [PubMed: 17313942]
70. Koyama E, Shibukawa Y, Nagayama M, Sugito H, Young B, Yuasa T, Okabe T, Ochiai T, Kamiya N, Rountree RB, Kingsley DM, Iwamoto M, Enomoto-Iwamoto M, Pacifici M. A distinct cohort of progenitor cells participates in synovial joint and articular cartilage formation during mouse limb skeletogenesis. *Dev Biol.* 2008; 316(1):62–73. [PubMed: 18295755]
71. Kronenberg HM. Developmental regulation of the growth plate. *Nature.* 2003; 423(6937):332–336. [PubMed: 12748651]
72. Park J, Gebhardt M, Golovchenko S, Perez-Branguli F, Hattori T, Hartmann C, Zhou X, deCrombrugge B, Stock M, Schneider H, von der Mark K. Dual pathways to endochondral osteoblasts: a novel chondrocyte-derived osteoprogenitor cell identified in hypertrophic cartilage. *Biol Open.* 2015; 4(5):608–621. [PubMed: 25882555]
73. Jing Y, Zhou X, Han X, Jing J, von der Mark K, Wang J, de Crombrugge B, Hinton RJ, Feng JQ. Chondrocytes directly transform into bone cells in mandibular condyle growth. *J Dent Res.* 2015; 94(12):1668–1675. [PubMed: 26341973]
74. Zhou X, von der Mark K, Henry S, Norton W, Adams H, de Crombrugge B. Chondrocytes transdifferentiate into osteoblasts in endochondral bone during development, postnatal growth and fracture healing in mice. *PLoS Genet.* 2014; 10(12):e1004820. [PubMed: 25474590]
75. Yang L, Tsang KY, Tang HC, Chan D, Cheah KS. Hypertrophic chondrocytes can become osteoblasts and osteocytes in endochondral bone formation. *Proc Natl Acad Sci USA.* 2014; 111(33):12097–12102. [PubMed: 25092332]
76. Swingler TE, Wheeler G, Carmont V, Elliott HR, Barter MJ, Abu-Elmagd M, Donell ST, Boot-Handford RP, Hajihosseini MK, Munsterberg A, Dalmay T, Young DA, Clark IM. The expression and function of microRNAs in chondrogenesis and osteoarthritis. *Arthritis Rheumatism.* 2012; 64(6):1909–1919. [PubMed: 22143896]
77. Gabler J, Ruetze M, Kynast KL, Grossner T, Diederichs S, Richter W. Stage-specific mirs in chondrocyte maturation: differentiation-dependent and hypertrophy-related miR Clusters and the miR-181 family. *Tissue Eng Part A.* 2015; 21(23–24):2840–2851. [PubMed: 26431739]

78. McAlinden A, Varghese N, Wirthlin L, Chang LW. Differentially expressed microRNAs in chondrocytes from distinct regions of developing human cartilage. *PLoS One*. 2013; 8(9):e75012. [PubMed: 24040378]
79. Gibson G, Asahara H. microRNAs and cartilage. *J Orthopaedic Res*. 2013; 31(9):1333–1344.
80. Hong E, Reddi AH. MicroRNAs in chondrogenesis, articular cartilage, and osteoarthritis: implications for tissue engineering. *Tissue Eng Part B*. 2012; 18(6):445–453.
81. Le LT, Swingle TE, Clark IM. Review: the role of microRNAs in osteoarthritis and chondrogenesis. *Arthritis Rheumatism*. 2013; 65(8):1963–1974. [PubMed: 23666813]
82. Shang J, Liu H, Zhou Y. Roles of microRNAs in prenatal chondrogenesis, postnatal chondrogenesis and cartilage-related diseases. *J Cell Mol Med*. 2013; 17(12):1515–1524. [PubMed: 24373548]
83. Mackay AM, Beck SC, Murphy JM, Barry FP, Chichester CO, Pittenger MF. Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. *Tissue Eng*. 1998; 4(4): 415–428. [PubMed: 9916173]
84. Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU. In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. *Exp Cell Res*. 1998; 238(1):265–272. [PubMed: 9457080]
85. Boeuf S, Richter W. Chondrogenesis of mesenchymal stem cells: role of tissue source and inducing factors. *Stem Cell Res. Ther*. 2010; 1(4):31. [PubMed: 20959030]
86. Beane OS, Darling EM. Isolation, characterization, and differentiation of stem cells for cartilage regeneration. *Ann Biomed Eng*. 2012; 40(10):2079–2097. [PubMed: 22907257]
87. Wang L, Li Z, Li Z, Yu B, Wang Y. Long noncoding RNAs expression signatures in chondrogenic differentiation of human bone marrow mesenchymal stem cells. *Biochem Biophys Res Commun*. 2015; 456(1):459–464. [PubMed: 25482444]
88. Barry F, Boynton RE, Liu B, Murphy JM. Chondrogenic differentiation of mesenchymal stem cells from bone marrow: differentiation-dependent gene expression of matrix components. *Exp Cell Res*. 2001; 268(2):189–200. [PubMed: 11478845]
89. Hardingham TE, Oldershaw RA, Tew SR. Cartilage, SOX9 and Notch signals in chondrogenesis. *J Anat*. 2006; 209(4):469–480. [PubMed: 17005019]
90. Zhang L, Chen S, Bao N, Yang C, Ti Y, Zhou L, Zhao J. Sox4 enhances chondrogenic differentiation and proliferation of human synovium-derived stem cell via activation of long noncoding RNA DANCR. *J Mol Histol*. 2015; 46(6):467–473. [PubMed: 26514989]
91. Yuan SX, Wang J, Yang F, Tao QF, Zhang J, Wang LL, Yang Y, Liu H, Wang ZG, Xu QG, Fan J, Liu L, Sun SH, Zhou WP. Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNBN1. *Hepatology*. 2016; 63(2):499–511. [PubMed: 25964079]
92. Chen L, Song Z, Huang S, Wang R, Qin W, Guo J, Lin Z. lncRNA DANCR suppresses odontoblast-like differentiation of human dental pulp cells by inhibiting wnt/beta-catenin pathway. *Cell Tissue Res*. 2016; 364(2):309–318. [PubMed: 26646542]
93. Maass PG, Rump A, Schulz H, Stricker S, Schulze L, Platzer K, Aydin A, Tinschert S, Goldring MB, Luft FC, Bähring S. A misplaced lncRNA causes brachydactyly in humans. *J Clin Invest*. 2012; 122(11):3990–4002. [PubMed: 23093776]
94. Vortkamp A, Lee K, Lanske B, Segre GV, Kronenberg HM, Tabin CJ. Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. *Science*. 1996; 273(5275): 613–622. [PubMed: 8662546]
95. Bi W, Deng JM, Zhang Z, Behringer RR, de Crombrughe B. Sox9 is required for cartilage formation. *Nat Genet*. 1999; 22(1):85–89. [PubMed: 10319868]
96. Pineault KM, Wellik DM. Hox genes and limb musculoskeletal development. *Curr Osteoporos Rep*. 2014; 12(4):420–427. [PubMed: 25266923]
97. Favier B, Le Meur M, Chambon P, Dolle P. Axial skeleton homeosis and forelimb malformations in Hoxd-11 mutant mice. *Proc Natl Acad Sci USA*. 1995; 92(1):310–314. [PubMed: 7816839]
98. Gerard M, Chen JY, Gronemeyer H, Chambon P, Duboule D, Zakany J. In vivo targeted mutagenesis of a regulatory element required for positioning the Hoxd-11 and Hoxd-10 expression boundaries. *Genes Dev*. 1996; 10(18):2326–2334. [PubMed: 8824591]

99. Hashimoto K, Yokouchi Y, Yamamoto M, Kuroiwa A. Distinct signaling molecules control Hoxa-11 and Hoxa-13 expression in the muscle precursor and mesenchyme of the chick limb bud. *Development*. 1999; 126(12):2771–2783. [PubMed: 10331987]
100. Salsi V, Zappavigna V. Hoxd13 and Hoxa13 directly control the expression of the EphA7 Ephrin tyrosine kinase receptor in developing limbs. *J Biol Chem*. 2006; 281(4):1992–1999. [PubMed: 16314414]
101. Li L, Liu B, Wapinski OL, Tsai MC, Qu K, Zhang J, Carlson JC, Lin M, Fang F, Gupta RA, Helms JA, Chang HY. Targeted disruption of Hotair leads to homeotic transformation and gene derepression. *Cell Rep*. 2013; 5(1):3–12. [PubMed: 24075995]
102. Carrion K, Dyo J, Patel V, Sasik R, Mohamed SA, Hardiman G, Nigam V. The long non-coding HOTAIR is modulated by cyclic stretch and WNT/ beta-CATENIN in human aortic valve cells and is a novel repressor of calcification genes. *PloS One*. 2014; 9(5):e96577. [PubMed: 24788418]
103. Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G. Genome regulation by polycomb and trithorax proteins. *Cell*. 2007; 128(4):735–745. [PubMed: 17320510]
104. Carlson HL, Quinn JJ, Yang YW, Thornburg CK, Chang HY, Stadler HS. LncRNA-HIT Functions as an epigenetic regulator of chondrogenesis through its recruitment of p100/CBP complexes. *PLoS Genet*. 2015; 11(12):e1005680. [PubMed: 26633036]
105. Richards EJ, Zhang G, Li ZP, Permuth-Wey J, Challa S, Li Y, Kong W, Dan S, Bui MM, Coppola D, Mao WM, Sellers TA, Cheng JQ. Long non-coding RNAs (LncRNA) regulated by transforming growth factor (TGF) beta: LncRNA-hit-mediated TGFbeta-induced epithelial to mesenchymal transition in mammary epithelia. *J Biol Chem*. 2015; 290(11):6857–6867. [PubMed: 25605728]
106. Kawai J, Shinagawa A, Shibata K, Yoshino M, Itoh M, Ishii Y, Arakawa T, Hara A, Fukunishi Y, Konno H, Adachi J, Fukuda S, Aizawa K, Izawa M, Nishi K, Kiyosawa H, Kondo S, Yamanaka I, Saito T, Okazaki Y, Gojobori T, Bono H, Kasukawa T, Saito R, Kadota K, Matsuda H, Ashburner M, Batalov S, Casavant T, Fleischmann W, Gaasterland T, Gissi C, King B, Kochiwa H, Kuehl P, Lewis S, Matsuo Y, Nikaido I, Pesole G, Quackenbush J, Schriml LM, Staubli F, Suzuki R, Tomita M, Wagner L, Washio T, Sakai K, Okido T, Furuno M, Aono H, Baldarelli R, Barsh G, Blake J, Boffelli D, Bojunga N, Carninci P, de Bonaldo MF, Brownstein MJ, Bult C, Fletcher C, Fujita M, Gariboldi M, Gustincich S, Hill D, Hofmann M, Hume DA, Kamiya M, Lee NH, Lyons P, Marchionni L, Mashima J, Mazzarelli J, Mombaerts P, Nordone P, Ring B, Ringwald M, Rodriguez I, Sakamoto N, Sasaki H, Sato K, Schonbach C, Seya T, Shibata Y, Storch KF, Suzuki H, Toyo-oka K, Wang KH, Weitz C, Whittaker C, Wilming L, Wynshaw-Boris A, Yoshida K, Hasegawa Y, Kawaji H, Kohtsuki S, Hayashizaki Y. Team RGERGPI, the FC. Functional annotation of a full-length mouse cDNA collection. *Nature*. 2001; 409(6821):685–690. [PubMed: 11217851]
107. Suzuki T, Hasso SM, Fallon JF. Unique SMAD1/5/8 activity at the phalanx-forming region determines digit identity. *Proc Natl Acad Sci US A*. 2008; 105(11):4185–4190.
108. Chimal-Monroy J, Rodriguez-Leon J, Montero JA, Ganan Y, Macias D, Merino R, Hurlé JM. Analysis of the molecular cascade responsible for mesodermal limb chondrogenesis: Sox genes and BMP signaling. *Dev Biol*. 2003; 257(2):292–301. [PubMed: 12729559]
109. Lehmann K, Seemann P, Stricker S, Sammar M, Meyer B, Suring K, Majewski F, Tinschert S, Grzeschik KH, Muller D, Knaus P, Nurnberg P, Mundlos S. Mutations in bone morphogenetic protein receptor 1B cause brachydactyly type A2. *Proc Natl Acad Sci USA*. 2003; 100(21):12277–12282. [PubMed: 14523231]
110. Baur ST, Mai JJ, Dymecki SM. Combinatorial signaling through BMP receptor IB and GDF5: shaping of the distal mouse limb and the genetics of distal limb diversity. *Development*. 2000; 127(3):605–619. [PubMed: 10631181]
111. Buckwalter JA. Osteoarthritis and articular cartilage use, disuse, and abuse: experimental studies. *J Rheumatol Suppl*. 1995; 43:13–5. [PubMed: 7752117]
112. Gilbertson EM. Development of periarticular osteophytes in experimentally induced osteoarthritis in the dog. A study using microradiographic, microangiographic, and fluorescent bone-labelling techniques. *Ann Rheum Dis*. 1975; 34(1):12–25. [PubMed: 1124952]

113. Guilak F. Biomechanical factors in osteoarthritis. *Best Pract Res Clin Rheumatol*. 2011; 25(6): 815–823. [PubMed: 22265263]
114. Hoch DH, Grodzinsky AJ, Koob TJ, Albert ML, Eyre DR. Early changes in material properties of rabbit articular cartilage after meniscectomy. *J Orthopaedic Res*. 1983; 1(1):4–12.
115. Moskowitz RW, Davis W, Sammarco J, Martens M, Baker J, Mayor M, Burstein AH, Frankel VH. Experimentally induced degenerative joint lesions following partial meniscectomy in the rabbit. *Arthritis Rheumatism*. 1973; 16(3):397–405. [PubMed: 4708019]
116. Pond MJ, Nuki G. Experimentally-induced osteoarthritis in the dog. *Ann Rheum Dis*. 1973; 32(4):387–388. [PubMed: 4726075]
117. Griffin TM, Fermor B, Huebner JL, Kraus VB, Rodriguiz RM, Wetsel WC, Cao L, Setton LA, Guilak F. Diet-induced obesity differentially regulates behavioral, bio-mechanical, and molecular risk factors for osteoarthritis in mice. *Arthritis Res Ther*. 2010; 12(4):R130. [PubMed: 20604941]
118. Wu CL, Diekman BO, Jain D, Guilak F. Diet-induced obesity alters the differentiation potential of stem cells isolated from bone marrow, adipose tissue and infrapatellar fat pad: the effects of free fatty acids. *Int J Obes (Lond)*. 2013; 37(8):1079–1087. [PubMed: 23164698]
119. Huggle T, Geurts J, Nuesch C, Muller-Gerbl M, Valderrabano V. Aging and osteoarthritis: an inevitable encounter? *J Aging Res*. 2012; 2012:950192. [PubMed: 22720159]
120. Goldring MB. Articular cartilage degradation in osteoarthritis. *HSS J*. 2012; 8(1):7–9. [PubMed: 23372517]
121. Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. *Ther Adv Musculoskelet Dis*. 2013; 5(2):77–94. [PubMed: 23641259]
122. Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. *Arthritis Rheumatism*. 2012; 64(6):1697–1707. [PubMed: 22392533]
123. Barter MJ, Bui C, Young DA. Epigenetic mechanisms in cartilage and osteoarthritis: DNA methylation, histone modifications and microRNAs. *Osteoarthritis Cartilage*. 2012; 20(5):339–349. [PubMed: 22281264]
124. Barter MJ, Young DA. Epigenetic mechanisms and non-coding RNAs in osteoarthritis. *Curr Rheumatol Rep*. 2013; 15(9):353. [PubMed: 23888362]
125. den Hollander W, Ramos YF, Bomer N, Elzinga S, van der Breggen R, Lakenberg N, de Dijkker WJ, Suchiman HE, Duijnisveld BJ, Houwing-Duistermaat JJ, Slagboom PE, Bos SD, Nelissen RG, Meulenbelt I. Transcriptional associations of osteoarthritis-mediated loss of epigenetic control in articular cartilage. *Arthritis Rheumatol*. 2015; 67(8):2108–2116. [PubMed: 25892573]
126. Fernandez-Tajes J, Soto-Hermida A, Vazquez-Mosquera ME, Cortes-Pereira E, Mosquera A, Fernandez-Moreno M, Oreiro N, Fernandez-Lopez C, Fernandez JL, Rego-Perez I, Blanco FJ. Genome-wide DNA methylation analysis of articular chondrocytes reveals a cluster of osteoarthritic patients. *Ann Rheum Dis*. 2014; 73(4):668–677. [PubMed: 23505229]
127. Gabay O, Sanchez C. Epigenetics, sirtuins and osteoarthritis. *Joint Bone Spine*. 2012; 79(6):570–573. [PubMed: 22738809]
128. Jeffries MA, Donica M, Baker LW, Stevenson ME, Annan AC, Humphrey MB, James JA, Sawalha AH. Genome-wide DNA methylation study identifies significant epigenomic changes in osteoarthritic cartilage. *Arthritis Rheumatol*. 2014; 66(10):2804–2815. [PubMed: 24980887]
129. Rushton MD, Young DA, Loughlin J, Reynard LN. Differential DNA methylation and expression of inflammatory and zinc transporter genes defines subgroups of osteoarthritic hip patients. *Ann Rheum Dis*. 2015; 74(9):1778–1782. [PubMed: 25854584]
130. Taylor SE, Li YH, Wong WH, Bhutani N. Genome-wide mapping of DNA hydroxymethylation in osteoarthritic chondrocytes. *Arthritis Rheumatol*. 2015; 67(8):2129–2140. [PubMed: 25940674]
131. Taylor SE, Smeriglio P, Dhulipala L, Rath M, Bhutani N. A global increase in 5-hydroxymethylcytosine levels marks osteoarthritic chondrocytes. *Arthritis Rheumatol*. 2014; 66(1):90–100. [PubMed: 24449578]
132. Rushton MD, Reynard LN, Barter MJ, Refaie R, Rankin KS, Young DA, Loughlin J. Characterization of the cartilage DNA methylome in knee and hip osteoarthritis. *Arthritis Rheumatol*. 2014; 66(9):2450–2460. [PubMed: 24838673]

133. Dudek KA, Lafont JE, Martinez-Sanchez A, Murphy CL. Type II collagen expression is regulated by tissue-specific miR-675 in human articular chondrocytes. *J Biol Chem*. 2010; 285(32):24381–24387. [PubMed: 20529846]
134. Steck E, Boeuf S, Gabler J, Werth N, Schnatzer P, Diederichs S, Richter W. Regulation of H19 and its encoded microRNA-675 in osteoarthritis and under anabolic and catabolic in vitro conditions. *J Mol Med*. 2012; 90(10):1185–1195. [PubMed: 22527881]
135. Liang WC, Fu WM, Wang YB, Sun YX, Xu LL, Wong CW, Chan KM, Li G, Wayne MM, Zhang JF. H19 activates Wnt signaling and promotes osteoblast differentiation by functioning as a competing endogenous RNA. *Sci Rep*. 2016; 6:20121. [PubMed: 26853553]
136. Huang Y, Zheng Y, Jia L, Li W. Long noncoding RNA H19 promotes osteoblast differentiation via TGF-beta1/Smad3/HDAC signaling pathway by deriving miR-675. *Stem Cells*. 2015; 33(12):3481–3492. [PubMed: 26417995]
137. Zhou J, Yang L, Zhong T, Mueller M, Men Y, Zhang N, Xie J, Giang K, Chung H, Sun X, Lu L, Carmichael GG, Taylor HS, Huang Y. H19 lncRNA alters DNA methylation genome wide by regulating S-adenosylhomocysteine hydrolase. *Nat Commun*. 2015; 6:10221. [PubMed: 26687445]
138. Xing D, Liang JQ, Li Y, Lu J, Jia HB, Xu LY, Ma XL. Identification of long noncoding RNA associated with osteoarthritis in humans. *Orthop Surg*. 2014; 6(4):288–293. [PubMed: 25430712]
139. Kim D, Song J, Han J, Kim Y, Chun CH, Jin EJ. Two non-coding RNAs, MicroRNA-101 and HOTTIP contribute cartilage integrity by epigenetic and homeotic regulation of integrin-alpha1. *Cell Signalling*. 2013; 25(12):2878–2887. [PubMed: 24018042]
140. Fu M, Huang G, Zhang Z, Liu J, Zhang Z, Huang Z, Yu B, Meng F. Expression profile of long noncoding RNAs in cartilage from knee osteoarthritis patients. *Osteoarthritis Cartilage*. 2015; 23(3):423–432. [PubMed: 25524778]
141. Liu Q, Zhang X, Dai L, Hu X, Zhu J, Li L, Zhou C, Ao Y. Long noncoding RNA related to cartilage injury promotes chondrocyte extracellular matrix degradation in osteoarthritis. *Arthritis Rheumatol*. 2014; 66(4):969–978. [PubMed: 24757148]
142. Song J, Ahn C, Chun CH, Jin EJ. A long non-coding RNA, GAS5, plays a critical role in the regulation of miR-21 during osteoarthritis. *J Orthopaedic Res*. 2014; 32(12):1628–1635.
143. Glasson SS, Blanchet TJ, Morris EA. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. *Osteoarthritis Cartilage*. 2007; 15(9):1061–1069. [PubMed: 17470400]
144. Su W, Xie W, Shang Q, Su B. The Long Noncoding RNA MEG3 Is Downregulated and Inversely Associated with VEGF Levels in Osteoarthritis. *Biomed Res Int*. 2015; 2015:356893. [PubMed: 26090403]
145. Pearson MJ, Philp AM, Heward JA, Roux BT, Walsh DA, Davis ET, Lindsay MA, Jones SW. Long intergenic noncoding RNAs mediate the human chondrocyte inflammatory response and are differentially expressed in osteoarthritis cartilage. *Arthritis Rheumatol*. 2016; 68(4):845–856. [PubMed: 27023358]
146. Gilbert, SF. *Developmental biology*. 9th. Sunderland, MA: Sinauer Associates; 2010. p. 80xxi, 711
147. Ash P, Loutit JF, Townsend KM. Osteoclasts derived from haematopoietic stem cells. *Nature*. 1980; 283(5748):669–670. [PubMed: 7354855]
148. Blair HC, Kahn AJ, Crouch EC, Jeffrey JJ, Teitelbaum SL. Isolated osteoclasts resorb the organic and inorganic components of bone. *J Cell Biol*. 1986; 102(4):1164–1172. [PubMed: 3457013]
149. Hall BK, Miyake T. Divide, accumulate, differentiate: cell condensation in skeletal development revisited. *Int J Dev Biol*. 1995; 39(6):881–893. [PubMed: 8901191]
150. Oberlender SA, Tuan RS. Expression and functional involvement of N-cadherin in embryonic limb chondrogenesis. *Development*. 1994; 120(1):177–187. [PubMed: 8119125]
151. Oberlender SA, Tuan RS. Spatiotemporal profile of N-cadherin expression in the developing limb mesenchyme. *Cell Adhes Commun*. 1994; 2(6):521–537. [PubMed: 7743138]
152. Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, Wright BD, Radtke F, Aguet M, Ferrara N. VEGF is required for growth and survival in neonatal mice. *Development*. 1999; 126(6):1149–1159. [PubMed: 10021335]

153. Haigh JJ, Gerber HP, Ferrara N, Wagner EF. Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. *Development*. 2000; 127(7):1445–1453. [PubMed: 10704390]
154. Vega RB, Matsuda K, Oh J, Barbosa AC, Yang X, Meadows E, McAnally J, Pomajzl C, Shelton JM, Richardson JA, Karsenty G, Olson EN. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. *Cell*. 2004; 119(4):555–566. [PubMed: 15537544]
155. Abzhanov A, Rodda SJ, McMahon AP, Tabin CJ. Regulation of skeletogenic differentiation in cranial dermal bone. *Development*. 2007; 134(17):3133–3144. [PubMed: 17670790]
156. Haworth KE, Healy C, Morgan P, Sharpe PT. Regionalisation of early head ectoderm is regulated by endoderm and prepatterns the orofacial epithelium. *Development*. 2004; 131(19):4797–4806. [PubMed: 15342462]
157. Lee SH, Fu KK, Hui JN, Richman JM. Noggin and retinoic acid transform the identity of avian facial prominences. *Nature*. 2001; 414(6866):909–912. [PubMed: 11780063]
158. Creuzet S, Couly G, Le Douarin NM. Patterning the neural crest derivatives during development of the vertebrate head: insights from avian studies. *J Anat*. 2005; 207(5):447–459. [PubMed: 16313387]
159. Trokovic N, Trokovic R, Mai P, Partanen J. Fgfr1 regulates patterning of the pharyngeal region. *Genes Dev*. 2003; 17(1):141–153. [PubMed: 12514106]
160. Trokovic N, Trokovic R, Partanen J. Fibroblast growth factor signalling and regional specification of the pharyngeal ectoderm. *Int J Dev Biol*. 2005; 49(7):797–805. [PubMed: 16172976]
161. Holleville N, Quilhac A, Bontoux M, Monsoro-Burq AH. BMP signals regulate Dlx5 during early avian skull development. *Dev Biol*. 2003; 257(1):177–189. [PubMed: 12710966]
162. Creuzet S, Schuler B, Couly G, Le Douarin NM. Reciprocal relationships between Fgf8 and neural crest cells in facial and forebrain development. *Proc Natl Acad Sci USA*. 2004; 101(14):4843–4847. [PubMed: 15041748]
163. Kang JS, Alliston T, Delston R, Derynck R. Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3. *EMBO J*. 2005; 24(14):2543–2555. [PubMed: 15990875]
164. Saydam O, Shen Y, Wurdinger T, Senol O, Boke E, James MF, Tannous BA, Stemmer-Rachamimov AO, Yi M, Stephens RM, Fraefel C, Gusella JF, Krichevsky AM, Breakefield XO. Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. *Mol Cell Biol*. 2009; 29(21):5923–5940. [PubMed: 19703993]
165. Zhu L, Xu PC. Downregulated LncRNA-ANCR promotes osteoblast differentiation by targeting EZH2 and regulating Runx2 expression. *Biochem Biophys Res Commun*. 2013; 432(4):612–617. [PubMed: 23438432]
166. Jia Q, Jiang W, Ni L. Down-regulated non-coding RNA (lncRNA-ANCR) promotes osteogenic differentiation of periodontal ligament stem cells. *Arch Oral Biol*. 2015; 60(2):234–241. [PubMed: 25463901]
167. Zuo C, Wang Z, Lu H, Dai Z, Liu X, Cui L. Expression profiling of lncRNAs in C3H10T1/2 mesenchymal stem cells undergoing early osteoblast differentiation. *Mol Med Rep*. 2013; 8(2):463–467. [PubMed: 23799588]
168. Backesjo CM, Li Y, Lindgren U, Haldosen LA. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. *J Bone Miner Res*. 2006; 21(7):993–1002. [PubMed: 16813520]
169. Cohen-Kfir E, Artsi H, Levin A, Abramowitz E, Bajayo A, Gurt I, Zhong L, D'Urso A, Toiber D, Mostoslavsky R, Dresner-Pollak R. Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor. *Endocrinology*. 2011; 152(12):4514–4524. [PubMed: 21952235]
170. Zhuang W, Ge X, Yang S, Huang M, Zhuang W, Chen P, Zhang X, Fu J, Qu J, Li B. Upregulation of lncRNA MEG3 promotes osteogenic differentiation of mesenchymal stem cells from multiple myeloma patients by targeting BMP4 transcription. *Stem Cells*. 2015; 33(6):1985–1997. [PubMed: 25753650]

171. Haddox CL, Han G, Anijar L, Binitie O, Letson GD, Bui MM, Reed DR. Osteosarcoma in pediatric patients and young adults: a single institution retrospective review of presentation, therapy, and outcome. *Sarcoma*. 2014; 2014:402509. [PubMed: 24976784]
172. Hagleitner MM, de Bont ES, Te Loo DM. Survival trends and long-term toxicity in pediatric patients with osteosarcoma. *Sarcoma*. 2012; 2012:636405. [PubMed: 23226967]
173. Chan LH, Wang W, Yeung W, Deng Y, Yuan P, Mak KK. Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression. *Oncogene*. 2014; 33(40): 4857–4866. [PubMed: 24141783]
174. Sathiyamoorthy S, Ali SZ. Osteoblastic osteosarcoma: cytomorphologic characteristics and differential diagnosis on fine-needle aspiration. *Acta Cytol*. 2012; 56(5):481–486. [PubMed: 23075887]
175. Bernthal NM, Federman N, Eilber FR, Nelson SD, Eckardt JJ, Eilber FC, Tap WD. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. *Cancer*. 2012; 118(23):5888–5893. [PubMed: 22648705]
176. Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. *J Clin Oncol*. 1987; 5(1):21–26. [PubMed: 3543236]
177. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, Pritchard J, Malpas JS, Baker AR, Kirkpatrick JA, Ayala AG, Shuster JJ, Abelson HT, Simone JV, Vietti TJ. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. *N Engl J Med*. 1986; 314(25):1600–1606. [PubMed: 3520317]
178. Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, Healey JH. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. *J Clin Oncol*. 1998; 16(7):2452–2458. [PubMed: 9667263]
179. Rosen G, Marcove RC, Huvos AG, Caparros BI, Lane JM, Nirenberg A, Cacavio A, Groshen S. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. *J Cancer Res Clin Oncol*. 1983; 106(Suppl):55–67. [PubMed: 6604058]
180. Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, Berdel WE, Serve H, Muller-Tidow C. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. *Oncogene*. 2003; 22(39):8031–8041. [PubMed: 12970751]
181. Wilusz JE, JnBaptiste CK, Lu LY, Kuhn CD, Joshua-Tor L, Sharp PA. A triple helix stabilizes the 3' ends of long noncoding RNAs that lack poly(A) tails. *Genes Dev*. 2012; 26(21):2392–2407. [PubMed: 23073843]
182. Yoshimoto R, Mayeda A, Yoshida M, Nakagawa S. MALAT1 long non-coding RNA in cancer. *Biochim Biophys Acta*. 2016; 1859(1):192–199. [PubMed: 26434412]
183. Dong Y, Liang G, Yuan B, Yang C, Gao R, Zhou X. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway. *Tumour Biol*. 2015; 36(3): 1477–1486. [PubMed: 25431257]
184. Cai X, Liu Y, Yang W, Xia Y, Yang C, Yang S, Liu X. Long noncoding RNA MALAT1 as a potential therapeutic target in osteosarcoma. *J Orthopaedic Res*. 2016; 34(6):932–941.
185. Fang D, Yang H, Lin J, Teng Y, Jiang Y, Chen J, Li Y. 17beta-estradiol regulates cell proliferation, colony formation, migration, invasion and promotes apoptosis by upregulating miR-9 and thus degrades MALAT-1 in osteosarcoma cell MG-63 in an estrogen receptor-independent manner. *Biochem Biophys Res Commun*. 2015; 457(4):500–506. [PubMed: 25592968]
186. Ji Q, Zhang L, Liu X, Zhou L, Wang W, Han Z, Sui H, Tang Y, Wang Y, Liu N, Ren J, Hou F, Li Q. Long non-coding RNA MALAT1 promotes tumour growth and metastasis in colorectal cancer through binding to SFPQ and releasing oncogene PTBP2 from SFPQ/ PTBP2 complex. *Br J Cancer*. 2014; 111(4):736–748. [PubMed: 25025966]
187. Ruan W, Wang P, Feng S, Xue Y, Li Y. Long non-coding RNA small nucleolar RNA host gene 12 (SNHG12) promotes cell proliferation and migration by upregulating angiominin gene expression in human osteosarcoma cells. *Tumour Biol*. 2016; 37(3):4065–4073. [PubMed: 26486328]

188. Li JP, Liu LH, Li J, Chen Y, Jiang XW, Ouyang YR, Liu YQ, Zhong H, Li H, Xiao T. Microarray expression profile of long noncoding RNAs in human osteosarcoma. *Biochem. Biophys Res Commun.* 2013; 433(2):200–206. [PubMed: 23466354]
189. Sun XH, Yang LB, Geng XL, Wang R, Zhang ZC. Increased expression of lncRNA HULC indicates a poor prognosis and promotes cell metastasis in osteosarcoma. *Int J Clin Exp Pathol.* 2015; 8(3):2994–3000. [PubMed: 26045809]
190. Pasic I, Shlien A, Durbin AD, Stavropoulos DJ, Baskin B, Ray PN, Novokmet A, Malkin D. Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma. *Cancer Res.* 2010; 70(1):160–171. [PubMed: 20048075]
191. Cong M, Li J, Jing R, Li Z. Long non-coding RNA tumor suppressor candidate 7 functions as a tumor suppressor and inhibits proliferation in osteosarcoma. *Tumour Biol.* 2016 [Epub ahead of print].
192. Wang Y, Yao J, Meng H, Yu Z, Wang Z, Yuan X, Chen H, Wang A. A novel long non-coding RNA, hypoxia-inducible factor-2alpha promoter upstream transcript, functions as an inhibitor of osteosarcoma stem cells in vitro. *Mol Med Rep.* 2015; 11(4):2534–2540. [PubMed: 25434862]
193. Min L, Hong S, Duan H, Zhou Y, Zhang W, Luo Y, Shi R, Tu C. Antidifferentiation noncoding RNA regulates the proliferation of osteosarcoma cells. *Cancer Biother Radiopharm.* 2016; 31(2): 52–57. [PubMed: 26986815]
194. Li F, Cao L, Hang D, Wang F, Wang Q. Long non-coding RNA HOTTIP is up-regulated and associated with poor prognosis in patients with osteosarcoma. *Int J Clin Exp Pathol.* 2015; 8(9): 11414–11420. [PubMed: 26617868]
195. Wang B, Su Y, Yang Q, Lv D, Zhang W, Tang K, Wang H, Zhang R, Liu Y. Overexpression of long non-coding RNA HOTAIR promotes tumor growth and metastasis in human osteosarcoma. *Mol Cells.* 2015; 38(5):432–440. [PubMed: 25728753]
196. Qian M, Yang X, Li Z, Jiang C, Song D, Yan W, Liu T, Wu Z, Kong J, Wei H, Xiao J. P50-associated COX-2 extragenic RNA (PACER) overexpression promotes proliferation and metastasis of osteosarcoma cells by activating COX-2 gene. *Tumour Biol.* 2016; 37(3):3879–3886. [PubMed: 26476537]
197. Ulaner GA, Vu TH, Li T, Hu JF, Yao XM, Yang Y, Gorlick R, Meyers P, Healey J, Ladanyi M, Hoffman AR. Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. *Hum Mol Genet.* 2003; 12(5):535–549. [PubMed: 12588801]
198. Tian ZZ, Guo XJ, Zhao YM, Fang Y. Decreased expression of long non-coding RNA MEG3 acts as a potential predictor biomarker in progression and poor prognosis of osteosarcoma. *Int J Clin Exp Pathol.* 2015; 8(11):15138–15142. [PubMed: 26823857]
199. Ma B, Li M, Zhang L, Huang M, Lei JB, Fu GH, Liu CX, Lai QW, Chen QQ, Wang YL. Upregulation of long non-coding RNA TUG1 correlates with poor prognosis and disease status in osteosarcoma. *Tumour Biol.* 2016; 37(4):4445–4455. [PubMed: 26499949]
200. Zhang CL, Zhu KP, Shen GQ, Zhu ZS. A long non-coding RNA contributes to doxorubicin resistance of osteosarcoma. *Tumour Biol.* 2016; 37(2):3737–3748.
201. Ponjavic J, Ponting CP, Lunter G. Functionality or transcriptional noise? Evidence for selection within long non-coding RNAs. *Genome Res.* 2007; 17(5):556–565. [PubMed: 17387145]
202. Smith MA, Gesell T, Stadler PF, Mattick JS. Widespread purifying selection on RNA structure in mammals. *Nucleic Acids Res.* 2013; 41(17):8220–8236. [PubMed: 23847102]
203. Washietl S, Hofacker IL, Lukasser M, Huttenhofer A, Stadler PF. Mapping of conserved RNA secondary structures predicts thousands of functional noncoding RNAs in the human genome. *Nat. Biotechnol.* 2005; 23(11):1383–1390. [PubMed: 16273071]
204. Nielsen MM, Tehler D, Vang S, Sudzina F, Hedegaard J, Nordentoft I, Orntoft TF, Lund AH, Pedersen JS. Identification of expressed and conserved human non-coding RNAs. *Rna.* 2014; 20(2):236–251. [PubMed: 24344320]
205. Torarinsson E, Yao Z, Wiklund ED, Bramsen JB, Hansen C, Kjems J, Tommerup N, Ruzzo WL, Gorodkin J. Comparative genomics beyond sequence-based alignments: RNA structures in the ENCODE regions. *Genome Res.* 2008; 18(2):242–251. [PubMed: 18096747]

206. Tarazona S, Garcia-Alcalde F, Dopazo J, Ferrer A, Conesa A. Differential expression in RNA-seq: a matter of depth. *Genome Res.* 2011; 21(12):2213–2223. [PubMed: 21903743]
207. Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, Poliakov A, Cao X, Dhanasekaran SM, Wu YM, Robinson DR, Beer DG, Feng FY, Iyer HK, Chinnaiyan AM. The landscape of long noncoding RNAs in the human transcriptome. *Nat Genet.* 2015; 47(3):199–208. [PubMed: 25599403]
208. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL, Pachter L. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat Protoc.* 2012; 7(3):562–578. [PubMed: 22383036]
209. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, Pachter L. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nat Biotechnol.* 2010; 28(5):511–515. [PubMed: 20436464]
210. Olivarius S, Plessy C, Carninci P. High-throughput verification of transcriptional starting sites by Deep-RACE. *BioTechniques.* 2009; 46(2):130–132. [PubMed: 19317658]
211. Raj A, van den Bogaard P, Rifkin SA, van Oudenaarden A, Tyagi S. Imaging individual mRNA molecules using multiple singly labeled probes. *Nat Methods.* 2008; 5(10):877–879. [PubMed: 18806792]
212. Cabili MN, Dunagin MC, McClanahan PD, Biaesch A, Padovan-Merhar O, Regev A, Rinn JL, Raj A. Localization and abundance analysis of human lncRNAs at single-cell and single-molecule resolution. *Genome Biol.* 2015; 16:20. [PubMed: 25630241]
213. van Heesch S, van Iterson M, Jacobi J, Boymans S, Essers PB, de Bruijn E, Hao W, MacInnes AW, Cuppen E, Simonis M. Extensive localization of long noncoding RNAs to the cytosol and mono- and poly-ribosomal complexes. *Genome Biol.* 2014; 15(1):R6. [PubMed: 24393600]
214. Werner MS, Ruthenburg AJ. Nuclear fractionation reveals thousands of chromatin-tethered noncoding RNAs adjacent to active genes. *Cell Rep.* 2015; 12(7):1089–1098. [PubMed: 26257179]
215. McHugh CA, Russell P, Guttman M. Methods for comprehensive experimental identification of RNA-protein interactions. *Genome Biol.* 2014; 15(1):203. [PubMed: 24467948]
216. Engreitz JM, Sirokman K, McDonel P, Shishkin AA, Surka C, Russell P, Grossman SR, Chow AY, Guttman M, Lander ES. RNA-RNA interactions enable specific targeting of noncoding RNAs to nascent Pre-mRNAs and chromatin sites. *Cell.* 2014; 159(1):188–199. [PubMed: 25259926]
217. Chu C, Quinn J, Chang HY. Chromatin isolation by RNA purification (ChIRP). *J Visualized Exp.* 2012; (61):e3912.
218. Simon MD, Wang CI, Kharchenko PV, West JA, Chapman BA, Alekseyenko AA, Borowsky ML, Kuroda MI, Kingston RE. The genomic binding sites of a noncoding RNA. *Proc Natl Acad Sci USA.* 2011; 108(51):20497–20502. [PubMed: 22143764]
219. McHugh CA, Chen CK, Chow A, Surka CF, Tran C, McDonel P, Pandya-Jones A, Blanco M, Burghard C, Moradian A, Sweredoski MJ, Shishkin AA, Su J, Lander ES, Hess S, Plath K, Guttman M. The Xist lncRNA interacts directly with SHARP to silence transcription through HDAC3. *Nature.* 2015; 521(7551):232–236. [PubMed: 25915022]
220. Lee HY, Haurwitz RE, Apffel A, Zhou K, Smart B, Wenger CD, Laderman S, Bruhn L, Doudna JA. RNA-protein analysis using a conditional CRISPR nuclease. *Proc Natl Acad Sci USA.* 2013; 110(14):5416–5421. [PubMed: 23493562]
221. Shechner DM, Hacisuleyman E, Younger ST, Rinn JL. Multiplexable, locus-specific targeting of long RNAs with CRISPR-Display. *Nat Methods.* 2015; 12(7):664–670. [PubMed: 26030444]
222. Pedersen JS, Bejerano G, Siepel A, Rosenbloom K, Lindblad-Toh K, Lander ES, Kent J, Miller W, Haussler D. Identification and classification of conserved RNA secondary structures in the human genome. *PLoS Comput Biol.* 2006; 2(4):e33. [PubMed: 16628248]
223. Fang R, Moss WN, Rutenberg-Schoenberg M, Simon MD. Probing xist RNA structure in cells using targeted structure-seq. *PLoS Genet.* 2015; 11(12):e1005668. [PubMed: 26646615]

224. Loughrey D, Watters KE, Settle AH, Lucks JB. SHAPE-Seq 2.0: systematic optimization and extension of high-throughput chemical probing of RNA secondary structure with next generation sequencing. *Nucleic Acids Res.* 2014; 42(21):e165.
225. Underwood JG, Uzilov AV, Katzman S, Onodera CS, Mainzer JE, Mathews DH, Lowe TM, Salama SR, Haussler D. FragSeq: transcriptome-wide RNA structure probing using high-throughput sequencing. *Nat Methods.* 2010; 7(12):995–1001. [PubMed: 21057495]
226. Liao Q, Liu C, Yuan X, Kang S, Miao R, Xiao H, Zhao G, Luo H, Bu D, Zhao H, Skogerbo G, Wu Z, Zhao Y. Large-scale prediction of long non-coding RNA functions in a coding-non-coding gene co-expression network. *Nucleic Acids Res.* 2011; 39(9):3864–3878. [PubMed: 21247874]
227. Lennox KA, Behlke MA. Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides. *Nucleic Acids Res.* 2016; 44(2):863–877. [PubMed: 26578588]
228. Goff LA, Rinn JL. Linking RNA biology to lncRNAs. *Genome Res.* 2015; 25(10):1456–1465. [PubMed: 26430155]
229. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, Heckl D, Ebert BL, Root DE, Doench JG, Zhang F. Genome-scale CRISPR-Cas9 knockout screening in human cells. *Science.* 2014; 343(6166):84–87. [PubMed: 24336571]
230. Necsulea A, Soumillon M, Warnefors M, Liechti A, Daish T, Zeller U, Baker JC, Grutzner F, Kaessmann H. The evolution of lncRNA repertoires and expression patterns in tetrapods. *Nature.* 2014; 505(7485):635–640. [PubMed: 24463510]
231. Guttman M, Garber M, Levin JZ, Donaghey J, Robinson J, Adiconis X, Fan L, Koziol MJ, Gnirke A, Nusbaum C, Rinn JL, Lander ES, Regev A. Ab initio reconstruction of cell type-specific transcriptomes in mouse reveals the conserved multi-exonic structure of lincRNAs. *Nat Biotechnol.* 2010; 28(5):503–510. [PubMed: 20436462]
232. Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, Rinn JL. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. *Genes Dev.* 2011; 25(18):1915–1927. [PubMed: 21890647]
233. Li L, Chang HY. Physiological roles of long noncoding RNAs: insight from knockout mice. *Trends Cell Biol.* 2014; 24(10):594–602. [PubMed: 25022466]
234. Penny GD, Kay GF, Sheardown SA, Rastan S, Brockdorff N. Requirement for Xist in X chromosome inactivation. *Nature.* 1996; 379(6561):131–137. [PubMed: 8538762]
235. Fitzpatrick GV, Soloway PD, Higgins MJ. Regional loss of imprinting and growth deficiency in mice with a targeted deletion of KvDMR1. *Nat Genet.* 2002; 32(3):426–431. [PubMed: 12410230]
236. Rapicavoli NA, Poth EM, Blackshaw S. The long non-coding RNA RNCR2 directs mouse retinal cell specification. *BMC Dev Biol.* 2010; 10:49. [PubMed: 20459797]
237. Ho TT, Zhou N, Huang J, Koirala P, Xu M, Fung R, Wu F, Mo YY. Targeting non-coding RNAs with the CRISPR/Cas9 system in human cell lines. *Nucleic Acids Res.* 2015; 43(3):e17. [PubMed: 25414344]
238. Clark MB, Johnston RL, Inostroza-Ponta M, Fox AH, Fortini E, Moscato P, Dinger ME, Mattick JS. Genome-wide analysis of long noncoding RNA stability. *Genome Res.* 2012; 22(5):885–898. [PubMed: 22406755]
239. Silva A, Bullock M, Calin G. The clinical relevance of long non-coding RNAs in cancer. *Cancers (Basel).* 2015; 7(4):2169–2182. [PubMed: 26516918]
240. Mouraviev V, Lee B, Patel V, Albala D, Johansen TE, Partin A, Ross A, Perera RJ. Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer. *Prostate Cancer Prostatic Dis.* 2016; 19(1):14–20. [PubMed: 26503110]
241. Salman JW, Schoots IG, Carlsson SV, Jenster G, Roobol MJ. Prostate specific antigen as a tumor marker in prostate cancer: biochemical and clinical aspects. *Adv Exp Med Biol.* 2015; 867:93–114. [PubMed: 26530362]
242. Crea F, Watahiki A, Quagliata L, Xue H, Pikor L, Parolia A, Wang Y, Lin D, Lam WL, Farrar WL, Isogai T, Morant R, Castori-Eppenberger S, Chi KN, Wang Y, Helgason CD. Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. *Oncotarget.* 2014; 5(3):764–774. [PubMed: 24519926]

243. Kumarswamy R, Bauters C, Volkman I, Maury F, Fetisch J, Holzmann A, Lemesle G, de Groote P, Pinet F, Thum T. Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. *Circ Res.* 2014; 114(10):1569–1575. [PubMed: 24663402]
244. Mohankumar S, Patel T. Extracellular vesicle long non-coding RNA as potential biomarkers of liver cancer. *Brief Funct Genomics.* 2016; 15(3):249–256. [PubMed: 26634812]
245. Takahashi K, Yan IK, Kogure T, Haga H, Patel T. Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer. *FEBS Open Bio.* 2014; 4:458–467.
246. Gezer U, Ozgur E, Cetinkaya M, Isin M, Dalay N. Long non-coding RNAs with low expression levels in cells are enriched in secreted exosomes. *Cell Biol Int.* 2014; 38(9):1076–1079. [PubMed: 24798520]
247. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007—an update. *J Gene Med.* 2007; 9(10):833–842. [PubMed: 17721874]
248. Corsi K, Chellat F, Yahia L, Fernandes JC. Mesenchymal stem cells, MG63 and HEK293 transfection using chitosan-DNA nanoparticles. *Biomaterials.* 2003; 24(7):1255–1264. [PubMed: 12527266]
249. Regnstrom K, Ragnarsson EG, Fryknas M, Koping-Hoggard M, Artursson P. Gene expression profiles in mouse lung tissue after administration of two cationic polymers used for nonviral gene delivery. *Pharm Res.* 2006; 23(3):475–482. [PubMed: 16463010]
250. Raftery RM, Tierney EG, Curtin CM, Cryan SA, O'Brien FJ. Development of a gene-activated scaffold platform for tissue engineering applications using chitosan-pDNA nanoparticles on collagen-based scaffolds. *J Control Release.* 2015; 210:84–94. [PubMed: 25982680]
251. Kurreck J, Wyszko E, Gillen C, Erdmann VA. Design of antisense oligonucleotides stabilized by locked nucleic acids. *Nucleic Acids Res.* 2002; 30(9):1911–1918. [PubMed: 11972327]
252. Subramanian RR, Wysk MA, Ogilvie KM, Bhat A, Kuang B, Rockel TD, Weber M, Uhlmann E, Krieg AM. Enhancing antisense efficacy with multimers and multi-targeting oligonucleotides (MTOs) using cleavable linkers. *Nucleic Acids Res.* 2015; 43(19):9123–9132. [PubMed: 26446989]
253. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-Ginossar N, Brandman O, Whitehead EH, Doudna JA, Lim WA, Weissman JS, Qi LS. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. *Cell.* 2013; 154(2):442–451. [PubMed: 23849981]
254. Thakore PI, D'Ippolito AM, Song L, Safi A, Shivakumar NK, Kabadi AM, Reddy TE, Crawford GE, Gersbach CA. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. *Nat Methods.* 2015; 12(12):1143–1149. [PubMed: 26501517]
255. Cheng AW, Wang H, Yang H, Shi L, Katz Y, Theunissen TW, Rangarajan S, Shivalila CS, Dadon DB, Jaenisch R. Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. *Cell Res.* 2013; 23(10):1163–1171. [PubMed: 23979020]
256. Perez-Pinera P, Kocak DD, Vockley CM, Adler AF, Kabadi AM, Polstein LR, Thakore PI, Glass KA, Ousterout DG, Leong KW, Guilak F, Crawford GE, Reddy TE, Gersbach CA. RNA-guided gene activation by CRISPR-Cas9-based transcription factors. *Nat Methods.* 2013; 10(10):973–976. [PubMed: 23892895]
257. Maeder ML, Linder SJ, Cascio VM, Fu Y, Ho QH, Joung JK. CRISPR RNA-guided activation of endogenous human genes. *Nat Methods.* 2013; 10(10):977–979. [PubMed: 23892898]
258. Hilton IB, D'Ippolito AM, Vockley CM, Thakore PI, Crawford GE, Reddy TE, Gersbach CA. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. *Nat Biotechnol.* 2015; 33(5):510–517. [PubMed: 25849900]
259. Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, Hsu PD, Habib N, Gootenberg JS, Nishimasu H, Nureki O, Zhang F. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. *Nature.* 2015; 517(7536):583–588. [PubMed: 25494202]
260. Pearson MJ, Philp AM, Heward JA, Roux BT, Walsh DA, Davis ET, Lindsay MA, Jones SW. Long intergenic non-coding RNAs mediate the human chondrocyte inflammatory response and are differentially expressed in osteoarthritis cartilage. *Arthritis Rheumatol.* 2016; 68(4):845–856. [PubMed: 27023358]




Figure 1. HOTAIR function in regulating HOXD gene expression. Expressed from the HOXC locus, HOTAIR binds to SUZ12 and EZH2, part of the PRC2 complex. HOTAIR acts *in trans* by recruiting the PRC2 complex to the HOXD locus and silences the locus by establishing H3K27me3 marks (30).




Figure 2. lncRNA-HIT and Hottip function in regulating Hoxa gene expression. (A) lncRNA-HIT binds to the p100/CBP complex and maintains H3K27ac marks at HoxA genes, resulting in gene activation (103). (B) Hottip acts *in cis* by recruiting the WDR5/MLL histone methyltransferase complex to the Hoxa genes, resulting in gene activation by establishing H3K4me3 marks (31).




Figure 3. Different mechanisms of H19 in osteogenesis. (A) H19 is processed into miR-675, which targets TGFB1 for degradation (135). (B) H19 acts as a sponge to sequester miR-141 and miR-22 away from their targets, thus leading to an upregulation of targeted mRNAs that may be required for osteoblast differentiation (134).




Figure 4. MALAT-1 function in osteosarcoma. (A) MALAT-1 IncRNA is not polyadenylated, but instead contains a triple helical domain at its 3' end that protects it from degradation (180). (B) MALAT-1 binds to SFPQ in nuclear speckles. This sequestration prevents the formation of the SFPQ/PTBP2 complex. Subsequently, unbound PTBP2 can induce tumor growth by increasing cellular proliferation and migration (185).

Table 1

Summary of identified lncRNAs involved in skeletal biology and disease.

Gene name	Gene symbol	ENSEMBL Gene ID	Expression pattern	Proposed function	Reference
Chondrogenesis associated transcript	<i>DAI/25942</i> Synonym: <i>C1STR</i>	ENSG00000260492	Genetic mutation results in brachydactyly type E (BDE)	Interacts with PTHLH <i>in trans</i> and with SOX9 <i>in cis</i>	(93)
Differentiation antagonizing non-protein coding RNA	<i>DANCR</i> Synonym: <i>ANCR</i>	ENSG00000226950	Upregulated during chondrocyte differentiation	May promote cell proliferation and differentiation toward the chondrocyte lineage	(90)
			Downregulated during osteogenesis	Recruits EZH2 to the RUNX2 promoter and suppresses RUNX2 expression	(165)
				Inhibits osteogenesis via suppression of Wnt/ β -catenin pathway.	(166)
			Upregulated in osteosarcoma		(193)
FOXO2 antisense RNA 1 Synonym: Osteosarcoma doxorubicin-resistance upregulated lncRNA	<i>FOXO2-AS1</i> Synonym: <i>ODRUL</i>	ENSG00000260944	Expression correlates with poor response to doxorubicin chemotherapy		(200)
Growth arrest-specific 5	<i>GAS5</i>	ENSG00000234741	Primarily expressed in the nucleus of healthy chondrocytes, and in the cytoplasm of OA chondrocytes	Induces catabolic effect by regulating miR-21	(142)
			Elevated in OA chondrocytes		(138, 139)
H19, imprinted maternally expressed transcript (<i>Mus musculus</i>)	<i>H19</i>	ENSMUSG00000000031	<i>H19</i> is upregulated by overexpression of <i>Hh</i> and <i>Yap1</i> . Overexpression of <i>Yap1</i> and <i>H19</i> is responsible for the pathogenesis of osteoblastic osteosarcoma		(173)
H19, imprinted maternally expressed transcript (<i>Homo sapiens</i>)	<i>H19</i>	ENSG00000130600	Highly expressed in mature chondrocytes	Functions downstream of SOX9. <i>H19</i> is processed into miR-675 that subsequently upregulates <i>COL2A1</i> .	(133)
			Elevated in OA chondrocytes		(134, 138, 139)
			Upregulated in osteogenesis	<i>H19</i> is processed into miR-675, which targets <i>TGFB1</i> for degradation.	(136)
				<i>H19</i> acts as a ceRNA, binding to miR-141 and miR-22, thus preventing their binding to target mRNAs.	(135)
HIF1A antisense RNA	<i>HIF1A-AS1</i>	ENSG00000258777		Knockdown of <i>HIF1a-AS1</i> decreases <i>HOXD10</i>	(168)

Gene name	Gene symbol	ENSEMBL Gene ID	Expression pattern	Proposed function	Reference
Highly upregulated in liver cancer conserved region	<i>HULC</i>	ENSG00000276019	Upregulated in osteosarcoma	expression	(189)
HOX transcript antisense RNA (<i>Mus musculus</i>)	<i>Hotair</i>	ENSMUSG000000086903	Hotair knockout mice exhibit patterning malformations in the limbs and lumbosacral junction	Recruits EZH2 and SUZ12 to the HoxD cluster and silences the locus.	(101)
HOX transcript antisense RNA (<i>Homo sapiens</i>)	<i>HOTAIR</i>	ENSG00000228630	Elevated in OA chondrocytes	Recruits EZH2 and SUZ12 to the HoxD cluster and silences the locus.	(138, 139)
			Upregulated in osteosarcoma		(195)
			Decreased in AVICs by cyclic stretch, leading to calcification	β -catenin is a stretch responsive signaling pathway that represses <i>HOTAIR</i>	(102)
HOXA transcript at the distal tip	<i>HOTTIP</i>	ENSG00000243766	Elevated in OA chondrocytes		(139)
			Upregulated in osteosarcoma		(194)
HOXA transcript induced by TGF β	<i>lnc-RNA-HIT</i> Synonym: <i>9530018H1/4RIK</i>	ENSMUSG00000102373	Expressed in the developing mouse limb	Binds to p100/CBP complexes to maintain active chromatin mark H3K27ac at the <i>HoxA4</i> locus	(104)
KCNK15 antisense RNA 1	<i>KCNK15-AS1</i> Synonym: <i>RPI1-445H22.4</i>	ENSG00000244558	Elevated in OA chondrocytes		(138)
Long intergenic non-protein coding RNA 707	<i>LINC00707</i>	ENSG00000238266	Downregulated during chondrogenesis		(87)
Long intergenic non-protein coding RNA 1589	<i>UNC01589</i> Synonym: <i>CTA-94TF9.9</i>	ENSG00000238120	Upregulated during chondrogenesis		(87)
Maternally expressed gene 3	<i>MEG3</i>	ENSG00000214548	Downregulated in osteoarthritis chondrocytes Increased during osteogenic differentiation	Upregulates <i>BMP4</i> by disrupting the interaction between the SOX2 and BMP4 promoter.	(144) (170)
			Decreased expression of <i>MEG3</i> is correlated with poor prognosis in osteosarcoma		(198)
Metastasis-associated lung adenocarcinoma transcript 1	<i>MALAT1</i>	ENSG00000278217	Upregulated in osteosarcoma		(183, 184)
			Downregulated in MG63 osteosarcoma cell line by high-dose estrogen	Sequesters SFPQ and disrupts the SFPQ/PTBP2 complex, resulting in PTBP2-mediated increases in cellular proliferation and migration.	(180, 185)

Gene name	Gene symbol	ENSEMBL Gene ID	Expression pattern	Proposed function	Reference
Not assigned	<i>CTD2574D22.4</i>	ENSG00000260114	Elevated in OA chondrocytes		(138)
Not assigned	<i>RPI1-815M8.1</i>	ENSG000000238042	Upregulated during chondrogenesis		(87)
PMS1 homolog 2, mismatch repair system component pseudogene 2	<i>PMS2L2</i>	ENSG00000278416	Elevated in OA chondrocytes		(138)
PTGS2 antisense NFKB1 complex-mediated expression regulator RNA Synonym: PS-associated COX2 extragenic RNA	<i>PACERR</i> Synonym: <i>PACER, PTGS2-AS1</i>	ENSG000000273129	Increased following IL1- β treatment of primary OA chondrocytes	Upregulates oncogene COX2 in an NF-KB dependent manner	(196)
Small nucleolar RNA host gene 12	<i>SNHG12</i>	ENSG00000197989	Upregulated in osteosarcoma		(187, 188)
Taurine upregulated 1	<i>TUG1</i>	ENSG00000253352	Increased expression is correlated with poor prognosis in osteosarcoma		(199)
Tumor-suppressor candidate 7	<i>TUSC7</i> Synonym: <i>LSAMP-AS3</i> <i>LOC285194</i>	ENSG00000243197	Downregulated in osteosarcoma		(190, 191)
Vimentin 2, pseudogene Synonym: Cartilage injury-related lncRNA	<i>VIM2P</i> Synonym: <i>lncRNA-CIR RPI1-162L10.1</i>	ENSG00000220548	Downregulated in OA chondrocytes		(141)
ZBED3 antisense RNA 1	<i>ZBED3-AS1</i>	ENSG00000250802	Upregulated during chondrogenesis		(87)